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Natural products are small-molecule secondary metabolites displaying 
considerable structural complexity and “privileged scaffolds”. They are able to 
bind several endogenous targets eliciting biological effects as chemical 
weapons or to convey information from one organism to another. 
Nowadays, medicinal plant drug discovery continues to provide new and 
important leads against various pharmacological targets. Therefore, the 
primary purpose of this PhD thesis has been a comprehensive characterization 
of the interactome profile and then the molecular mechanism of action of 
bioactive natural molecules. Achieving this in an effective, unbiased and 
efficient manner subsists as a significant challenge for the new era in drug 
discovery and optimization. Indeed, the full understanding of the mechanism 
of action of natural molecules could lead to a number of advantages: first of 
all, exploit their full therapeutic potential, the identification of side effects or 
toxicity, or the ability to set up target-based assays and to allow structure 
activity relationships studies to guide medicinal chemistry efforts towards lead 
optimization. 
In my research project, the attention was paid on ent-kaurane diterpenes, a 
class of natural terpenoids with a great structural variability and a wide 
spectrum of biological activities. Firstly, I focused on the determination of the 
interactome of a semi synthetic compound 15-ketoatractyligenin methyl ester. 
This compound has been previously reported to possess high antiproliferative 
activity against several solid tumor-derived cell lines. In this regard, I decided 
to investigate the mechanism of action of this actratylignin derivative 
researching first of all its molecular targets, responsible for the biological 
activity. In order to achieve this goal, I used a chemical proteomic approach 
first. This study led to the identification of PPARγ as the main cellular partner 
of this compound; achieved results were supported and validated through 
different biological assays. 
Subsequently, I studied another diterpene: oridonin. This molecule has been 
shown to have multiple biological activities. Among them, the anticancer 
activity has been repeatedly reported by many research groups. With the aim 
of expanding and validate our knowledge about this molecule, also seen the 
limitations of the fishing for partners method, I decided to use two orthogonal 
compound-centric proteomics approaches to define the possible protein 
target(s) of oridonin. Using this strategy HSP70 and nucleolin were identified. 
Therefore, several in vitro and in cell tests have been performed to validate the 
interaction of oridonin with these proteins, and to evaluate its effect on their 
activity. Some of these tests were developed and optimized during my period 
of research abroad at the Massachusset General Hospital- Center for System 
Biology -Harvard Medical School; in that twelve months period I expanded 
my knowledge into the techniques useful for the study of the mechanism of 
action of a small molecule, also applying experimental methods 
complementary to proteomics and focusing on the use of high-resolution 
intravital microscopy imaging for drug pharmacology. 
 






1.1 Importance of plant secondary metabolites in drug discovery 
The use of natural substances, particularly plant small molecules, to control 
human diseases is a centuries old practice that has led to the discovery of more 
than half of all “modern” pharmaceuticals (Katz L. & Baltz R.H. 2016). Thus, 
there is increasing interest in the clues from traditional uses of plant extracts to 
guide new drug discovery;to have an idea of the sigfnificance of hetnobotanic 
use of plant drugs it is sufficient just to consider the wide consumption of 
medicinal plants in the traditional Chinese medicine to cure and prevent 
diseases. Besides, more than half of humanity does not have access to modern 
medicine they rely on traditional treatments (Cordell & Colvard, 2012). 
Actually, natural products play a significant role in the drug discovery and 
development process and this is particularly evident in the areas of cancer and 
infectious diseases, where over 60% and 75% of therapeutic agents have to be 
considered of natural origin. This contribution seems impressive, but it can be 
easily explained in the light of the chemical and evolutionistic proprieties 
shown by natural products. First of all, they exhibit a wide range of 
pharmacophores and a high degree of stereochemistry. Therefore, they have 
been - and they are still - an invaluable source of inspiration for organic 
chemist to synthesize novel drug candidates (Beghyn T. et al. 2008; Hunter P. 
2008; Koehn Koehn F.E. & Carter G.T. 2005), since they provide a new 
starting point for new synthetic compound with diverse structures and often 
with multiple stereocenters that can be challenging synthetically (Clardy J. & 
Walsh C. 2004; Nicolaou K.C. & Snyder S.A. 2004; Peterson E.A. & 
Overman L.E. 2004). Indeed, many structural features common to natural 
products (e.g., chiral center, aromatic rings, complex ring system, degree of 
molecule saturation and number and ratio of heteroatoms) are expected to 
contribute to their ability to provide hits even against the more difficult 
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screening targets, such as protein-protein interactions (Balunas M.J. & 
Kinghorn A.D. 2005). Moreover natural products may have the additional 
advantage of being natural metabolites: compounds that are efficient as drugs 
have been suggested to have the propriety of ‘metabolite-likness’(Herty J. et 
al. 2009). Then, natural compounds are a good starting point for the setting up 
of libraries to test for drug discovery, not only for their complex and 
diversified chemical space but also for their ability to interact with 
biomolecules. 
Although natural products have not been developed to bind to human proteins, 
they can do it very well. There are two main theories to explain this 
phenomenon: the first, widely accepted, is that it is the result of long-term co-
evolution within biological communities; interacting organism, that evolved in 
close proximity to one another, developed compounds that could influence the 
biological process of neighboring species (Ji H.F. et al. 2009). The second 
theory, advanced by Konrad T. et al. and called xenohormesis, (Figure 1) is 
based on the hypothesis that there have been common ancestors of plants and 
animals able to synthesize a large number of stress- induced secondary 
metabolites; animals and fungi, that feed on plants, gradually lost the capacity 
to synthesize these low-weight molecular compounds, but retained the ability 
to sense these chemical cues in plants, possibly in order to detect when plants 
were stressed and gain an early warning of changing environmental condition 














Fig.1: The Xenohormesis hypothesis.  
Adopted from Konrad T.H. & David A.S. 2008 
 
In fact, natural products are evolutionary preselected thus representing 
structural requirements for the binding to proteins. Their structural scaffolds 
represent the biologically relevant and prevalidated fractions of chemical 
structure space explored by nature so far (Koch M.A. et al. 2005). Moreover, 
recently Stuart Schreiber, Paul Clemons and their colleagues at the Broad 
Institute in Boston performed a bioinformatics analysis of natural product 
targets, thus demonstrating that natural molecules statically tend to target 
proteins with a high number of protein– protein interactions that are 
particularly essential to an organism (Dancík V. et al. 2010). This observation 
is consistent with the common role played by natural products as chemical 
weapons against predators or competitors. 
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Despite the success of plant molecules as drugs and the large number of 
benefits they show, they are losing favor among drug developers. One reason 
is the perceived “dirtiness” of plant molecules: a molecule is considered 
“dirty” if it interacts with numerous endogenous proteins. Such compounds 
presumably are more likely to have negative “off target” effects than a 
molecule that specifically targets a single protein. Flying in the face of this 
dogma, there are examples of plant molecules that, despite interacting with 
multiple human enzymes and receptors are surprisingly safe (Prasad S. & 
Tyagi A.K. 2015). Take for example salicylic acid or curcumin, are 
surprisingly powerful and nontoxic although they are two multitarget 
molecules. In fact, having multi-target molecules could be a winning strategy 
to face various diseases. It has been increasingly recognized that, in several 
pathologies, there are a large number of mutated genes and/or modified 
proteins that disrupt multiple pathways, which normally exhibit extensive 
biological cross-talk and redundancy. Therefore, the development of ‘magic 
bullet’ drugs that bind selectively to single protein targets also appears less 
clinically useful, since, interfering with a single target and/or pathway may not 
abrogate the disease. Moreover, a promising strategy for mitigating an 
acquired drug resistance or suppress disease, is to simultaneously inhibit 
multiple molecular pathways, either by using several agents in combination or 
by using a single agent that concurrently blocks multiple targets or pathways. 
 
1.2 Terpenes 
The terpenes are an important class of plant secondary metabolites which 
constitute a vast family of natural substances structurally different from each 
other, whose starting elements for the biosynthesis are the isoprene units.  
They are produced by diverse organisms to perform an assortment of 
biological functions in varying ecological contexts. They are derived 
biosynthetically from units of isoprene, which has the molecular formula 
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C5H8. Isoprene itself does not undergo the building process, but rather 
activated forms, isopentenyl pyrophosphate (IPP or also isopentenyl 
diphosphate) and dimethylallyl pyrophosphate (DMAPP or also dimethylallyl 
diphosphate), are the actual components in the biosynthetic pathway. 
Although all terpenoids are synthesized from two five-carbon building blocks, 
the structures and functions vary widely. Many terpenes have shown several 
biological activities. Isoprenoids and derivatives play a critical role in all 
living systems: the cell structure, systems of electron transport in cell-cell 
signals (steroids, abscisic acid, gibberellic acid, phytol ecc.), in the structure of 
organisms and interactions between them. Some isoprenoids play a role in 
plant defense systems against attack by micro-organisms and insects, act as 
allelopathic compounds in plant-insect and plant-environment (Lange B.M. et 
al., 2000).Furthermore, they are used for the treatment of human diseases. In 
fact, there is a wide spectrum of biological and pharmacological activities for 
these types of substances such as antibacterial, antifungal, antiparasitic, anti-
inflammatory, cytotoxic and antitumoral (Coll J. et al. 2007, Evans F.J. & 
Taylor S.E. 1983). Although they shown all of these activities, approximately 
35,000 terpenes have been identified and the majority of possible functions of 
these molecules are unknown. Then, it would be interesting to study this class 
of natural molecules to find out its potential biological effects and uses in 
therapy. 
 
1.3 Drug discovery today  
Drug discovery is an inherently complex process with an industrial base, 
through which potential new medicines are identified and it involves a wide 
range of scientific disciplines, including biology, chemistry and 
pharmacology. When chemistry had reached a degree of maturity that allowed 
its principles and methods to be applied to problems outside of chemistry itself 
and when pharmacology had become a well-defined scientific discipline in its 
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own right, drug discovery as we know it today began its career; in fact, this 
discipline is not much older than a century. Drug research has contributed 
more to the progress of medicine during the past century than any other 
scientific factor. During the first half of last century, drug research was shaped 
and enriched by several new technologies, all of which left their imprint on 
drug discovery and on therapy. Genomic era and then rapid DNA sequencing, 
combinatorial chemistry, cell-based assays, and automated highthroughput 
screening (HTS) has led to a “new” concept of drug discovery. Therefore, in 
the last decade dramatic changes in the approaches to biomedical discovery 
occurred, also due to the advent of massively parallel sequencing technologies 
to sequence genomes, the ability to characterize the transcriptome and an 
improved ability to evaluate the proteome (Roti G. & Stegmaier K. 2012). 
The development of a new drug can generally be divided into phases (Figure 
2). The first is the preclinical phase, which usually takes 3 to 4 years. If 
successful, this phase is followed by an application to national or international 
drug agencies (DA) as an investigational new drug (IND). After an IND is 
approved, the next steps are clinical phases 1, 2 and 3, which require 
approximately 1, 2, and 3 years, respectively, for completion. Importantly, 
throughout this process the DA and investigators leading the trials 
communicate with each other, so that such issues as safety are monitored. The 
manufacturer then files a new drug application (NDA) with the DA for 
approval. This application can either be approved or rejected, or the DA might 
request further study before making a decision. Following acceptance, the DA 
can also request that the manufacturer conduct additional post-marketing 






Fig.2: Overview of drug discovery process. 
Adopted from: Beom-Su Jang 2013 
 
Generally, drug development often fails at late stages, after significant cost 
and time investments (Paul S.M. et al. 2010). It’s enough to consider a current 
price tag of over US $1 billion per drug and an average of 13 years of 
investment (Paweletz C.P. et al. 2011; Kola I. & Landis J. 2004; Collins I. & 
Workman P. 2006). Furthermore, only three out of ten approved drugs manage 
to recover their respective development costs. Therefore, the large upfront 
time and monetary expenditures limit the number of drugs that can be moved 
from the bench to the clinic. Actually, drugs fail in the clinic for two main 
reasons; the first is that they do not work and the second is that they are not 
safe. To accelerate drug development, and subsequently reduce exorbitant 
costs and high failure rates, the pharmaceutical industry needs to increase its 
overall R&D efficiency, not just productivity (Paul S.M. et al. 2010). In order 
to solve this problem, participation of academic centers in aspects of drug 
discovery and development beyond target identification and clinical trials is 
always been significant contributors to the discovery of new drugs in therapies 
(Shamas-Din A. & Schimmer A.D. 2015). 
In the typical drug development process, small-molecule ligands are identified 
by screening compound libraries against purified targets, using suitable 
biochemical assays. Hits derived from such screens are then further improved 
in an iterative medicinal chemistry process that includes profiling and 
validation in cell-based in vitro assays. This approach relies heavily on high-
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throughput screening methods, empirical and experimental compound 
selection and optimization, and the development of relevant animal models of 
disease. Additionally, computational techniques, including drug docking 
simulations and quantitative SAR (QSAR), are increasingly employed to 
improve the efficiency in lead compound optimization (Vinegoni C. et al. 
2015). In this regard, academic institutions developed several techniques and 
skills to evaluate the best candidate in the drug discovery process: they have 
established high-throughput screening platforms, formed medicinal chemistry 
teams, and built capabilities in pharmacokinetic studies with the aim of 
developing small-molecule drugs. Thus, the aim of these institutions is to 
identify and validate new therapeutic targets through biological studies and 
testing new drugs developed by the pharmaceutical industry in clinical trials. 
That’s why drug discovery in academic centers represent a unique opportunity 
for the industry. Therefore, since they do not consider necessarily issues 
related to market share and profitability, investigators can pursue drug 
candidates for targets of scientific interest. In addition, chemical probes that do 
not reach the stage of clinical trials are important experimental tools, since the 
probes can be used to reveal new biological insights. Finally, academic 
investigators can make important contributions to the rationale for 
development of new therapeutic agents, even if the intellectual property rights 
of the drug are held by others. 
However, advancing drugs from academic institutions into clinical trials 
remains challenging, and these institutions face common obstacles. In fact, 
heavy investment in money and time is the major obstacle to be overcome. 
One solution to this problem is for academic groups to replace “old” drug 
allowing the rapid evaluation of them into the clinical trial phase. The 
repositioning of thalidomide for myeloma, for example, is a dramatic success 
but there will likely be few examples of this strategy that show similar impact 
(Shamas-Din A. & Schimmer A.D. 2015). 
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An important challenge now is how to best exploit these new capabilities for 
therapeutic benefit. Thus, it is very important to know not only 
pharmacokinetic and pharmacodynamic parameters of a drug but above all its 
mechanism of action. Target identification and confirmation for small 
molecules is often the rate limiting step in drug discovery. Although drugs can 
be approved without a clear knowledge of their  target and/or mode of action, 
the full characterization of the protein binding profile of a small molecule is an 
important prerequisite for a complete picture of the biology behind it. In fact, 
complete comprehension of a drug leads many advantages in terms of 
improvement and potential of the molecule itself and in terms of versatility of 
the same, also allowing its possible use against more pathologies. In this 
regard proteomic approaches fits very well in the macro complex of drug 
discovery. Proteomics is an essential and crucial method to discover and 
explain drugs, not only because of the knowledge of the effects of drug 
candidates on their protein targets, but also to shed light on the cellular 
mechanisms behind the observed phenotype (Guo S. et al. 2013). 
 
1.4 Proteomic in drug discovery: the state of the art 
The publication of the full human genome sequence in 2003 by the 
International Human Genome Sequencing Consortium is a crucial milestone in 
the history of genetic research (Yan S.K. et al. 2015). The completion of 
human genome has created much excitement from the impact that this wealth 
of information is likely to have on the process of drug discovery and 
development (Reiss T. 2001; Lander E.S. et al., 2001). It has been postulated 
that scientists could use genomic information to identify and validate a host of 
new drug targets and tailor specific drugs based on an individual’s detailed 
genetic makeup (Cockett M. et al., 2000). Although this new field of genomics 
holds many promises, it is clear that analysis of DNA and/or RNA content 
alone is not sufficient to understand cell biology and disease. However, 
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analysis of the information produced by genomics, when measured against 
comparable information regarding protein expression, has led to the 
conclusion that message abundance fails to correlate with protein quantity 
(Nutall M.E. 2001). Further, post-translational processes such as protein 
modifications or protein degradation remain unaccounted for in genomic 
analysis (Anderson L & Seilhamer J 1997; Mann M. 1999). Since both cell 
function and its biochemical regulation depend on protein activity, and the 
correlation between message level and protein activity is low, the mere 
measurement of expression has proven to be inadequate. Consequently, the 
development of drug-discovery technologies has begun to shift from genomics 
to proteomics (Simpson R.J. & Dorow D.S. 2001). 
Proteomics, as a scientific field, is defined as the study of the protein products 
of the genome, and their interactions and functions. Hence, the proteins 
expressed at a given time in a given environment constitute a proteome (Dove 
A. 1999). From a technology viewpoint, traditional proteomics involves 
separation of proteins in a proteome, coupled to a means of identification. This 
science is very challenging since protein levels vary widely with both cell type 
and environment (Bichsel V.E. et al., 2001). Second, unlike genomics, which 
can amplify benefits from the amplification of single genes using the 
polymerase chain reaction (PCR), protein science has no comparable 
amplification method (Blackstock W.P. & Weir M.P. 1999). Third, proteomics 
is complicated by the fact that the absolute quantity of protein is of limited 
interest to drug discovery, because protein activities are highly regulated post-
translationally (Srinivas P.R. et al. 2001). Therefore, proteins can be abundant, 
yet possess little activity. Finally, because proteins interact functionally in 
vivo, protein–protein and protein–small molecule interactions need to be 
evaluated in processes of interest (Cravatt B.F. & Sorensen E.J. 2001). 
The metabolism of a cell or of an entire organism is mainly regulated by 
proteins, acting individually and, more frequently, in pathways. In particular, 
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the function of a protein can be defined on the basis of its interactions, and 
pathways are cascades of specific protein interactions that are necessary to 
activate distinct cellular functions. Genetic mutations or environmental factors 
deregulate these pathways, leading to disease conditions. A detailed 
knowledge of the pathways active inside the cell and of how they are deranged 
in a particular pathology is fundamental for drug discovery as it allows the 
identification of new drug targets. Since the pharmacologic effects of a drug 
can only be appreciated when its interactions with cellular components are 
clearly delineated, an integrated deconvolution of drug target interactions for 
each drug is necessary. The wide use of proteomic in drug target identification 
has enhanced our confidence in improving our understanding of the molecular 
mechanisms of these drugs. In fact, with the development of related high-
throughput analytical technologies and mass spectrometry, proteomics has 
been rapidly developed in various research fields. Thus, an unprecedented 
number of biological targets have been tested, and various technologies 


















Fig.3: Main applications of functional, chemical and clinical proteomics in drug discovery. 
Adopted from Savino R. et al. 2012 
 
As mentioned before, proteomic is spread in different fields, namely 
functional, chemical and clinical proteomics, all going to somehow impact on 
biomarker and drug discovery processes (Figure3). 
The proteome records the flow of information that starting within the cells, 
through the intercellular protein network, goes beyond the extracellular 
microenvironment up to come to the blood microenvironment (Matta A. et al., 
2010). Accordingly, the proteome may reflect immediate and characteristic 
changes in response to disease processes and external stimulation. By the 
means of proteomic tools such as mass spectrometry (MS), it is possible to 
qualitatively and quantitatively reveal molecular profiles contained in healthy 
or clinical samples. Consequently, MS technologies offer the opportunity to 
screen and discovery simultaneously multiple biomarkers, which consist of a 
pattern of up- or down-regulated molecules (proteins, peptides, metabolites, 
organic molecules) representative of a given (healthy/disease) condition. 
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Basically, clinical proteomics covers all MS-based preclinical and basic 
science studies aimed at discovering and understanding the role of proteins in 
pathological processes in order to facilitate the early diagnosis of disease, the 
prognosis prediction, the identification of new therapeutic targets and the 
evaluation of treatment response (Beretta L. 2007; Matt P. et al. 2008). 
Another emerging research area in the proteomic is functional proteomics, 
aimed to monitor and analyze the spatial and temporal properties of the 
molecular networks and fluxes involved in living cells (Godovac-
Zimmermann J. & Brown L.R. 2001). It is focused on the generation of 
information about proteins, such as expression levels, interacting partners, 
post-translational modifications (PTMs) and activity, which all contribute to 
elucidate pathways active inside the cells and, ultimately, to a functional 
understanding of biological systems.. In recent years, functional proteomics 
has been used to analyze not only the formation of specific protein-protein 
interactions, but alsoto understand how these interactions lead to the assembly 
of macromolecular protein complexes that are regulated by PTMs and which 
affect pathway functions. In particular, these approaches are addressed towards 
two major targets: the elucidation of biological functions of unknown proteins 
and the definition of cellular mechanisms at the molecular level. In the cells, 
many proteins display their biological functions through the rapid and 
transient association within large protein complexes. Understanding protein 
functions as well as unraveling molecular mechanisms within the cell then 
depend on the identification of the interacting protein partners. The association 
of an unknown protein with partners belonging to a specific protein complex 
involved in a particular mechanism would be strongly suggestive of its 
biological function (Gavin A.C. et al. 2002; Ho Y. et al. 2002). Furthermore, a 
detailed description of the cellular signaling pathways might greatly benefit 




Finally a powerful weapon to profile previously uncharacterized proteins via 
identifying drug target interactions is chemical proteomics: a multidisciplinary 
research area integrating biochemistry and cell biology with organic synthesis 
and MS. Chemical proteomics comes in two different flavors: (i) activity based 
probe profiling (ABPP), which focuses on the enzymatic activity of a 
particular protein family, and (ii) a compound-centric approach, which focuses 
on characterizing the molecular mechanism of action of an individual 
bioactive small molecule (Rix U. & Superti-Furga G. 2009). Thus, they also 
serve different purposes. ABPP detects members of a defined class of enzymes 
that are active under certain conditions-for example, in a disease. This method 
can lead to the identification of new proteins with the respective biochemical 
activity, or it can be applied to determine the selectivity profile of drugs 
targeting an enzyme family via pretreatment of the lysate with the drug of 
interest and subsequent labeling and identification of the remaining enzymes 
using appropriate reactive probes. Compound centric chemical proteomics 
consists of classical drug affinity chromatography that is similar to the method 
used for decades but that is now performed in combination with modern high-
resolution MS analysis and statistics or bioinformatics for subsequent 
identification of binding proteins (Savino R. et al., 2012). 
Finally, understanding protein function and unraveling cellular mechanisms at 
the molecular level constitute a major need in modern biology. Therefore, 
chemical proteomics is an initial technology that is useful in clinical testing 
and drug development. 
 
1.5 Scope of thesis 
Naturally occurring secondary metabolites are small molecules displaying 
considerable structural complexity and “privileged scaffolds”. They are able to 
bind several endogenous targets, eliciting biological effects as chemical 
weapons or as information vectors from one organism to another. Concerning 
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the human use, medicinal plant drug discovery continues to provide new and 
important leads against various diseases including cancer, HIV/AIDS, 
Alzheimer’s, malaria, and pain. Therefore, the overall aim of this Ph.D. study 
was to set-up, optimize, develop, and apply proteomics methods to elucidate 
the molecular mechanisms of action of bioactive natural molecules. It is 
indeed evident that the full understanding of these mechanisms could lead to a 
number of advantages: first of all, exploit the full therapeutic potential of 
promising compounds, the identification of their side effects or toxicity, or the 
ability to set up target-based assays. Moreover, it would allow performing 
structure activity relationships studies to guide medicinal chemistry efforts 
towards lead optimization. Achieving this in an effective, unbiased and 
efficient manner subsists as a significant challenge for the new era in drug 
discovery and optimization. Therefore, protein sample preparation, 
fractionation, high-throughput LC-MS/MS, data analysis, and, in particular, 
label free and chemical proteomic approaches were used. 
 
1.5.1 Outline of the thesis 
This research paid attention on diterpenes, a class of natural terpenoids with a 
wide structural variability and known spectrum of biological activities. Firstly, 
(Chapter 2) the determination of the interactome of a semi synthetic 
compound 15-ketoatractyligenin methyl ester is described. This compound has 
been previously reported to possess high antiproliferative and cytoxocitity 
activities against several solid tumor-derived cell lines. Therefore, we select it 
to investigate its mechanism of action, through the identification of the 
molecular targets responsible for its biological activity. In order to achieve this 
goal, a chemical proteomic approach was used; the emerged results were 
subsequently validated by biophysics, biological and bioinformatic assays. 
In the Chapter 3 the chemical-biological study of oridonin is discussed. This 
diterpene has been shown to have multiple biological activities. Among them, 
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the anticancer activity has been repeatedly reported by many research groups. 
With the aim of expanding and validate our knowledge about this molecule, 
we decided to use several approaches for the identification of its possible 
targets in cell. More in details, two orthogonal compound-centric proteomics 
approaches were used. Moreover, to validate the interaction of oridonin with 
these proteins, and to evaluate its effect on their activity several in vitro and in 
cell tests have been performed. 
Finally, to expand my knowledge into the techniques useful for the study of 
the mechanism of action of a small molecule, methods complementary to 
proteomics have been applied. In particular, in Chapter 4 new orthogonal 
techniques useful for the study of the mechanism of action of drugs and the 
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2.1 15-ketoatractyligenin methyl ester (SR2017) 
Ent kaurenes represent one of the most important classes of diterpenoids and 
they are constituted by a perhydrophenantrene unit fused with a cyclopentane 
unit forming a bridge between carbons C-8 and C-13 (Hanson J.R. 2009). 
These diterpenes have been shown to possess several biological activities and 
they are present in different plant species belonging to several families such as 
Asteraceae, Euphorbiaceae, Apiaceae, Lamiaceae and other families. Thus, 
they can be used as drug or lead compounds (Sun H.D. et al. 2006; García 
P.A. et al. 2007; Wang L. et al. 2011). 
Atractyligenin, the nor-ent-kaurane diterpene aglycon of the glycoside 
atractyloside originally extracted from the roots of Atractylis gummifera L. 
(Popat A. et al. 2001), exerts a weak hibition of oxidative phosphorylation in 
the mitochondria of hepatocytes and some anti-proliferative effects towards 
several cancer cell lines, but it also shows a significant toxicity for normal 
cells. Therefore, atractylgenin is considered an unsafe compound, and its high 
toxicity of this compound is due to its strychnine-like action, producing 
convulsions of a hypoglycemic type 2 (Santi R. & Luciani, S.1978; 
Klingenberg, M. 1989). Atractyligenin and other related compounds are quite 
common in nature (Piozzi F. et al. 1967). They are present in different species: 
Wedelia glauca (Schteingart C.D. & Pomilio A.B. 1984), Iphinona aucheri 
(Roeder E. et al. 1994), Drymaria arenariodes (Vargas D. et al. 1988) and 
were implicated in the death of cattle, camels, and other livestock that 
accidentally ingested these plants. Moreover, they are present in Coffea beans 
(arabica and to a lesser extent robustica). It has been suggested that 
atractylosides may possibly be responsible for the statistical link between 
coffee drinking and pancreatic cancer.  
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In order to overcame the high toxicity of atractylgenin, several semisynthetic 
analogues were synthesized. Among these the 15- ketoatractyligenin methyl 
ester, here named SR2017 (Figure 1), showed the higher potency as anticancer 
drug, having anti-proliferative and pro-apoptotic activity towards different 
cancer cell lines with IC50 in the order of nano molar (Rosselli S. et al. 2007). 
Studies performed in vitro and in vivo, revealed that treatment of cancer cells 
with SR2017 affects Akt activation inhibiting the PI3K pathway (Cotugno R. 
et al. 2014). Even if in literature there are several papers regarding bio-
pharmacological and toxicological effects of this molecule, few data are 
available concerning the identification of the SR2017 molecular target(s). 








Fig.1: Chemical structure of SR2017 
 
2.2 Aims of the project 
In the attempt to discover and develop new drugs, the full understanding of the 
mechanism of action at a molecular level of bioactive compounds is an 
essential step. Actually, the mere observation of the effects of chemical 
entities on cells, tissues or organisms is not enough to consider them for 
further uses or optimizations. Therefore, unbiased approaches aimed to the 
identification of the molecular target(s) of action of promising molecules are 
emerging as a required starting point for many pharmaceutical and 
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biochemical researches. In that field, proteomic-based studies play a central 
role, potentially allowing to describe all the possible interactors of a selected 
compound (Rix U. & Superti-Furga G. 2008). In this regard in the present 
study, to define the possible protein target(s) of the semi synthetic diterpene 
SR2017 we used a chemical proteomic approach. This study allowed us to 
identify a list of possible targets, that were confirmed and validate using 
orthogonal experimental approaches. Moreover, the effects of SR2017 on the 
biological activity of its target(s) were investigated, as well as the binding 
mode of this diterpene to its protein partner(s). The achieved results would 
permit to further optimize the compound for a possible therapeutic use. 
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Results and discussion 
 
2.3 Identification of the putative 15-ketoatractyligenin methyl ester 
targets by chemical proteomics 
To attempt the identification of the molecular target(s) of 15-
ketoatractyligenin methyl ester (SR2017), responsible for its activity, a 
chemical proteomics approach was used. This is one of the most versatile 
methods to profile cellular targets of selected drug candidates, and it is based 
on compound-immobilized affinity chromatography (Katayama H. & Oda Y. 
2007; Dal Piaz F. et al. 2013). The chemical immobilization of a small 
molecule ligand is usually achieved through suitable functional group. For the 
immobilization of SR2017, the hydroxyl group at position C-2 of the 
diterpene, not fundamental to its biological activity (Rosselli S. et al. 2007), 
was modified by an epoxy-activated sepharose resin. Reaction conditions were 
selected in order to prevent the modification of the α,β-unsaturated carbonyl 
group, essential for the activity of this class of diterpenes (Lee I.S. et al. 1996; 
Wijeratne E.M. et al. 2012). All the modification steps were monitored by 
HPLC; the whole procedure led to 80% of immobilization of SR2017 on the 
solid support used. 
The obtained drug-linked beads were incubated with protein extracts from 
Jurkat cells (Human T cell lymphoblast-like cell line), selected for their 
previously demonstrated susceptibility to SR2017 (Cotugno R. et al. 2014). 
After 30 minutes of incubation, the beads were extensively washed to remove 
any non-specifically interacting protein. Negative control experiments were 
simultaneously performed, using the same resin capped with ethanolamine to 
distinguish between specifically bound components and background 




Fig.2: Workflow of chemical proteomic approach used for SR2017 
 
The proteins tightly bound to each resin were eluted and resolved by SDS-
PAGE; the gel lanes containing the proteins eluted from the beads modified 
with SR2017 and the control ones were cut in 10 pieces, digested with trypsin, 
and analyzed by high resolution nanoLC MS/MS. Resulting MS and MS/MS 
data were analyzed by Mascot Search Engine software. Chemical proteomic 
experiments were performed in triplicate and only proteins identified in all the 
experiments were taken into account; moreover, proteins identified from both 
SR2017-modified and control beads were excluded. Using this strategy, it was 
possible to identify the molecular chaperone heat shock protein 60 (Hsp60), 
and the nuclear receptor peroxisome proliferator-activated receptor gamma 
(PPARɣ) as putative protein targets of our diterpene (Figure 3). 
 





2.4 Targets validation by Surface Plasmon Resonance  
The ability of SR2017 to interact with each of the proteins identified in the 
chemical proteomics experiments was assayed by surface plasmon resonance 
(SPR). SPR is an optical technique, based on the evanescent wave 
phenomenon, able to measure changes in refractive index onto a sensor 
surface, and it is suitable for characterizing macromolecular interactions. The 
binding between a compound in solution and its ligand immobilized on the 
sensor surface results in a change of the refractive index, that could be 
monitored in real time allowing the measurement of association and 
dissociation rates; therefore, different concentration of the diterpene were 
injected on each of the putative protein target, singularly immobilized on 
sensor chips (Dal Piaz F. et al. 2009). Obtained sensorgrams (Figure 4A) 
clearly showed a significant interaction of SR2017 with PPARɣ (Festa C. et 
al. 2012); a software aided elaboration of SPR results allowed measuring an 
equilibrium dissociation constants (KD) of 89.3 ± 5.5 nM for the 
SR2017/PPARɣ complex. Conversely, no affinity of the diterpene towards 
Hsp60 was observed (Figure 4B). 
 
Fig.4: A) Sensograms obtained from the binding of SR2017 to PPARɣ; B) Sensograms 
obtained from the binding of SR2017 to Hsp60. 
 
Therefore, considering all these data we decided to perform an in-depth 
investigation on the biological role of SR2017 in the interaction with this 
protein. PPARɣ is a member of the PPARs subfamily (peroxisome 
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proliferator-activated receptors) of the nuclear receptor of ligand-inducible 
transcription factors (Laudet V. et al. 1992). It probably is the main regulator 
of adipocites differentiation in human, but also plays a key role in lipid and 
glucose metabolism equilibrium, thus controlling cell proliferation (Tontonoz 
P. & Spiegelman B.M. 2008). Therefore, this protein is considered a 
pharmacologic target for metabolic dysfunctions (Choi J.H. et al. 2010), and 
for cancer (Reka A.K. et al. 2010). Several thiazolidinediones have been 
identified as PPARɣ agonists, and some of them have be approved for type 2 
diabetes therapy (Meggs D.G. et al. 1998; Kumar S. et al. 1998); however, 
some problems concerning the cardiovascular safety and possible 
hepatotoxicity of these drugs were observed (Watkins P.B. & Whitcomb R.W 
1998; Nissen S.E. & Wolski K 2010). Therefore, there is still a significant 
requirement of new types of PPARɣ ligands, possibly acting by a mechanism 
different from that of thiazolidinediones. Recently, some bioactive compounds 
derived from plants have been described as promising activators of PPARɣ 
(Wang L. et al. 2014). On these basis, the identification of PPARɣ as a 
possible molecular target of SR2017 was interesting, since modulation of 
PPARɣ activity could account for many of the cellular effects previously 
described for this compound (Cotugno R. et al. 2014). Indeed, a pro-apoptotic 
activity mediated by inhibition of the PI3K/Akt system was reported for 
several PPARɣ activators (Moon L. et al. 2011; Kulkarni A.A. et al. 2011; 
Honda A. et al. 2009). Therefore, we performed different experiment in order 
to get more details. 
 
2.4.1 Selectivity of 15-ketoatractyligenin methyl ester towards different 
isoform of PPARγ 
PPAR nuclear receptor is a big family including three different isoforms, 
PPARɣ, PPARα and PPARδ encoded by different genes. Therefore, to 
evaluate the selectivity of SR2017 towards PPARγ, this compound was also 
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subjected to SPR analyses on PPARα and PPARδ, two proteins structurally 
and functionally related to PPARγ (Fruchart J.C. 2009; Reilly S.M. & Lee 
C.H. 2008). All the SPR experiments were performed using the full length 
proteins. 
PPARδ and PPARα were immobilized on a sensor chip and increasing 
concentration of our diterpene were injected. No binding occurred between 
SR2017 and PPARδ; conversely, some interaction of this compound with 
PPARα was observed, but the KD measured (1.32 ± 0.08 µM) was about 50 
time higher than that measured for the PPARγ/SR2017 complex. A 
comparison between the sensorgrams acquired for the interaction of SR2017 
with PPARα and PPARγ reveals that the binding phases are similar, but there 
are clearly different kinetics of dissociation: PPARα/SR2017 complex was 
completely dissociated after less than 50 s, whereas PPARγ/SR2017 complex 
dissociation required long times and remains uncompleted. 
 
2.5 Structural characterization of SR2017/PPARɣ complex 
The SR2017/PPARɣ complex appeared to be very stable, as inferred by the 
measured low koff; (see Table 1) moreover, SPR sensorgrams showed that the 
dissociation of this complex required long times and remains uncompleted. 
This data, and the presence in the PPARɣ amino acidic sequence of a cysteine 
residue (Cys285), highly reactive towards nucleophile groups such as a α,β-
unsaturated ketones (Shiraki T. et al. 2005), prompted us to investigate the 
possible formation of a covalent bond between our diterpene and the nuclear 
receptor. Such bond could indeed be almost partially responsible for the high 
stability of the complex. In that aim, we performed a classic MS-based peptide 
mapping on the SR2017/PPARɣ complex using trypsin as proteolytic agent, to 
investigate the presence of covalently modified peptides. This analysis 
allowed us covering most of the protein sequence. Besides, a doubly charged 
ion at m/z 659,8481 was observed suggesting the presence of the peptide 281-
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288 covalently bound to SR2017; this hypothesis was confirmed by MS/MS 
analysis of this ion, thus reveling the modification occurring to Cys285 via 








Fig.5: High resolution mass spectrum and MS/MS data of peptide 281-288 covalently bound 
to SR2017 
 
2.6 15-ketoatractyligenin methyl ester is a bona fide PPARγ ligand and 
requires the binding to C285 for its transcriptional activity 
To verify if SR2017 is a bona fide PPARγ ligand able to activate PPARγ-
mediated transcription, we transiently transfected a PPRE-TK-luciferase-
reporter plasmid in HEK293 cells (Human Embryonic Kidney 293) that stably 
express an exogenous PPARγ (in addition to the endogenous protein). In 
collaboration with Prof. Vittorio Colantuoni from the University of Sannio, it 
was possible to evaluate the biological relevance of SR2017 in vitro. More in 
details, HEK293 cells were selected as they express a fixed and known amount 
of PPARγ, so that the differences in luciferase activity are due to the different 
ligand used. 
First, we tested the antiproliferative effect of SR2017 on HT-29 colon-cancer 
derived cells and compared the achieved results with those observed for 
rosiglitazone, a fully characterized PPARγ agonist (Hong G. et al. 2003). Cells 
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were cultured for 24 and 48 hs in the presence of increasing amounts of 
SR2017 or rosiglitazone, and counted (Figure 6). 15-Ketoatractyligenin 
methyl ester displayed a dosage-dependent inhibition of cell growth that was 
more pronounced than that produced by rosiglitazone. This stronger effect 
suggests that it likely activates specific antiproliferative and/or proapoptotic 
pathways. 
Once established the cytotoxic effect of SR2017 also on this cell model, 
trasfected HEK 293 cells were treated with increasing concentrations of 
rosiglitazone or SR2017 for 24 h and harvested for luciferase activity 48 h 
later. Rosiglitazone induced luciferase activity in a dose-dependent manner 
reaching a peak at 0.8 µM and declining at higher concentrations as illustrated 
in Figure 7. Therefore, it was possible to validate the interaction of SR2017 
with PPARγ. The obtained results displayed a transactivation activity of 
SR2017 that was about 40% lower than the full agonist rosiglitazone, with a 
peak at 1 µM. These results demonstrate that SR2017 can be considered a 














Fig.6: To assess the effect of SR2017 on exponentially growing HEK293 cells, cells were 
treated with increasing doses of SR2017 or rosiglitazone (1,5 and 10 µM). Cells were 
collected and counted after 24 and 48h.  
 
Finally, we asked whether the binding of SR2017 to Cys285 in the ligand-
binding pocket is required for the PPARγ transcriptional activity. In fact, 
previous results (see 2.5) shown the covalent interaction of SR2017 with this 
cysteine and its implication on the stabilization of the complex. To this goal 
we transiently transfected basal HEK293T cells with the PPRE-TK-luciferase-
reporter plasmid along with the expression vectors for the wild-type PPARγ1 











Fig.7: Transient transfection assay of the PPRE-luciferase reporter gene in human HEK293T 
cells stably expressing an exogenous Flag-tagged wild type PPARγ1. After transfection, cells 
were treated for 24 h with rosiglitazone or SR2017 respectively, at the indicated doses. 
Luciferase activity is reported as fold induction after normalization to β-galactosidase activity 
used as transfection control. 
 
Cells were exposed for 24 h either to the vehicle alone or two concentrations 
of rosiglitazone and SR2017 shown to produce the highest induction; 
luciferase activity was measured in the cell extracts 48 h later. Rosiglitazone 
was able to bind both the wild type and mutant receptor with similar affinity 
and stimulate equivalent luciferase activity. SR2017 interacted with wild type 
PPARγ and stimulated 40 % less luciferase activity than rosiglitazone, in line 
with being a partial agonist, as reported above. Strikingly, the interaction of 
SR2017 with the C285A mutant resulted in an even lower luciferase activity 
(Figure 8). These results show that the C285A mutation does not influence 
rosiglitazone-induced PPARγ transcriptional activity, while it impairs the 
induction elicited by SR2017, clearly demonstrating that the binding to this 
amino-acid residue is absolutely required for stimulating PPARγ 






Fig.8: Human HEK293T cells were cotransfected with the PPRE-luciferase reporter gene 
along with wild-type PPARγ1 or its (Cys285Ala) mutant version. After transfection, cells 
were treated for 24 h with rosiglitazone or SR2017 at the indicated concentrations. Luciferase 
activity is reported as fold induction after normalization to β-galactosidase activity used as 
transfection control. 
 
2.7 Molecular docking of SR2017/PPARγcomplex 
SR2017 is determined to be a partial agonist covalently bound to PPARγ in the 
current work (Figure 5). The covalent coupling of the ligand to Cys285 of 
PPARγ is the result of a Michael addition (conjugate addition) for which the 
organic reaction is well established and illustrated in Figure 9. The Michael 
acceptor contains an electron withdrawing group conjugated to an activated 







Fig.9: Mechanism of covalent coupling of SR2017 to Cys285 of PPARγ 
 
Thus, in collaboration with Prof. Antonio La Vecchia from the University of 
Naples Federico II, we chose to employ the covalent docking protocol 
CovDock ( Zhu, K. et al. 2014; Toledo-Warshaviak D. et al. 2014.) 
implemented in the in the Schrödinger Suite (Schrödinger, LLC, New York, 
NY, 2015) in order to visualize possible conformational states of the Cys285 
thioether resulting from a reaction with compound SR2017, assuming that its 
chemical reactivity (vide supra) is relevant in the context of the protein. 
CovDock uses different tools of the Schrödinger Suite to mimic distinct stages 
of covalent inhibitor binding. The first step is a classical noncovalent docking 
with an alanine mutation of the nucleophilic side chain followed by an 
automated bond formation and a second docking step with the covalent bond 
in place. The basic concept of the software is that a covalently bound ligand 
has to adopt an energetically favorable unbound pose before bond formation 
occurs and that these unbound poses do not change dramatically during the 
reaction pathway, because conformational sampling is done solely prior the 
noncovalent docking step. Docking was carried out employing the publicly 
available X-ray crystal structure of PPARγ in complex with the partial agonist 
LT175 (PDB code: 3B3K) (Montanari R. et al. 2008). 
A low-energy pose of SR2017 covalently bound to Cys285 was predicted by 
CovDock, and this conformation, which adopts a R configuration at position 
16 of the Michael acceptor, is stabilized by several H-bonds with the key 
residues in the β-sheet subpocket.  
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Unlike rosiglitazone, which takes a U-shape conformation in the ligand-
binding pocket and wrap around H3 to directly contact the AF-2 helix (H12), 
SR2017 occupies the region of PPAR delimited by the H3 and the -sheet (-
sheet sub-pocket) and makes no contact with H12 or residues involved in co-
activator recruitment (Figure 10a,c), as already observed in other structures of 
complexes with partial agonists, such as the complexes with BVT.13, MRL-
24, and nTZDpa (Bruning, J. B. et al. 2007). In contrast, the full agonist 
rosiglitazone occupies roughly 40% of the ligand-binding site of PPARγ in a 
U-shaped conformation and consists of a polar head and hydrophobic tail. The 
polar head makes a net of the H-bonds with Ser289, His323, His449, and 
Tyr473 PPARγ side chains, while forming a hydrophobic region with Phe363, 
Gln286, Phe282, and Leu469. Despite the fact that SR2017 binds in a different 
mode than rosiglitazone, occupying the -sheet sub-pocket, the ent-kaurane 
skeleton of SR2017 overlaps with the hydrophobic region of rosiglitazone 
when the two structures are superposed (Figure 10b).  
The carbonyl and the ethereal oxygens of the ester group at position 4 of the 
ligand form two H-bonds, one with the NH backbone of Ser342 (located at the 
-sheet) and one with both NH2 and N
ε
 of Arg288 side chain on H3. The 
hydroxyl group at position 2 establishes a H-bond with the C=O backbone of 
Ile281 (dOH-O = 2.8 Å) as well as a very weak H-bond (dOH-N = 4.1 Ǻ) with the 
side chain of His266, located at the Ω loop that links H2 to H3. Non-polar 
contacts are observed along the full extension of the SR2017 molecule. These 
contacts start at the Ω-loop of the protein, and extend all the way through the 
ligand binding pocket. Residues involved in these interactions include Phe264 
(part of the Ω-loop), Ile281, Gly284, and Phe287 on H3, Val339, Ile341 and 




Fig.10: a) and c) Binding mode of SR2017 (yellow sticks) into the PPAR binding site 
represented as a bluemarine ribbon model. b) C

superposition of the complexes of PPARγ 
with SR2017 and rosiglitazone (green sticks, PDB code 2PRG). Only amino acids located 
within 4 Å of the bound ligand are displayed (white sticks) and labeled. The Ω-loop, a flexible 
loop region between H2' and H3, and the β sheet region of the LBD, are displayed. H-bonds 
discussed in the text are depicted as dashed black lines. 
 
Recent experimental evidences showed that PPARγ partial agonists, that is 
ligands that lack direct contact with H12 but can still activate PPARγ to a 
lesser extent, use alternative mechanisms not involving the stabilization of 
H12, but rather the stabilization of H3 and the β-sheets (Bruning, J.B et al. 
2007) and/or modifications in the structure and dynamics of the flexible region 
known as Ω-loop, a flexible loop region comprising ~15 residues between H20 
and H3 spanning D260-K275 (Waku T et al. 2009b; Waku T. et al. 2009; Puhl 
A.C. et al. 2012; Hughes T.S et al. 2014).Structural comparison of SR2017 
with the previously published partial PPARγ agonists BVT.13, MRL-24, and 
nTZDpa reveals closely related interactions with PPARγ. All of these ligands 
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occupy the same binding site and interact similarly with H3 and the β-sheet. 
Their carboxyl or ester groups interact directly with Ser342 of the β-sheet. H3 
is always stabilized by a ligand carboxyl or hydroxyl group forming a direct or 
a water-mediated H-bond. Ligand binding to PPARγ seems to induce a 
cooperative folding transition between the H3 and β-sheet regions because the 
stability of these structural elements appears to be strongly correlated. Because 
the cyclin-dependent kinase 5 (Cdk5) recognition site extends into the first β-
strand of PPARγ, structural stabilization of the β-sheet region, elicited by 
SR2017 and other ligands, presumably renders Ser273 inaccessible to the 
kinase, protecting the receptor from phosphorylation, as originally proposed 
by Choi J.H. et al. 2010. 
 
2.8 Screening of 15-ketoatractyligenin methyl ester analogous using SPR 
analysis 
In order to identify the structural feature playing a pivotal role in the 
SR2017/PPARɣ interaction, we investigated the affinity of some SR2017 
analogous (compounds 2-9, Figure 3) towards this protein using SPR analyses. 
In particular, diterpenes with different functional groups and stereochemistry 
















Fig.11: Structure of compounds 1-9. Compound 1 is SR2017 
 
All these compounds displayed an affinity towards the  PPARγ ligand binding 
domain (PPARɣLBD) lower than that of SR2017 (Table 1). In particular, 
compounds whose bi-cyclic portion was clearly different from that of 1 
(SR2017), did not interact with the protein, regardless of the presence of the α-
β unsaturated keto-group (see compounds 8 and 9); on the other hand, 
elimination of the α-β unsaturated keto-group from SR2017 structure 
significantly affected interaction with PPARɣLBD, strongly increasing both 
thermodynamic (KD) and kinetic (koff) dissociation constants (compounds 2 
and 3). Finally, the presence of a free acidic function prevented interaction of 








































Table 1: Thermodynamic and kinetic constants measured by SPR for 
compounds 1-9 and rosiglitazone injected on immobilized PPARɣ. 
 
 
Compound KD (nM) koff (s
-1
) 
1 (SR2017) 89.3 0.0015 
2 1856 0.051 
3 4587 0.096 
4 no binding 
 5 no binding 
 6 no binding 
 7 no binding 
 8 no binding 
 9 no binding 
 Rosiglitazone 320.5 0.0286 
 
2.9 Discussion 
Natural compounds represent an incomparable source of bioactive chemical 
entities. However, their use is largely limited by the poor knowledge of their 
molecular mechanism and of their actual targets. In particular, plant 
metabolites carrying reactive groups are often considered unspecific and, 
therefore, poorly interesting; however, recent studies – also performed using 
proteomic based approaches- suggested that this is not always true. In the 
present study, we demonstrated that 15-ketoatractyligenin methyl ester 
(SR2017) selectively interacts with a specific protein (PPARγ), even if in its 
structure is present a α,β-unsaturated ketone reactive towards thiol groups. 
However, the formation of the covalent bond involving Cys285 is both 
required for the PPARγ/SR2017 complex stabilization and for the protein 
activation. The binding mode of SR2017 to the protein, with the ligand 
occupying the PPARγ β-sheet sub-pocket, suggested that SR2017 is a PPARγ 
partial agonist. This hypothesis was confirmed by studies on PPARγ activation 
by SR2017, in comparison with that achieved using the full agonist 
rosiglitazone. Recent findings revealed that some partial agonists show high 
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insulin sensitivity and significant activity, but side effects lower than PPARγ 
full agonist; therefore, SR2017 could be a promising lead for the development 
of new therapeutic and/or biochemical tool. 
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Materials and methods 
 
Materials 
Solvents and water (HPLC grade) were purchased from Romil (ROMIL Ltd, 
Cambridge, UK). Recombinant human PPARγ ligand binding domain 
(PPARγLBD) consisting of the region 195-477 of PPARγ, was purchased 
from Bertin-Pharma (Bertin-Pharma, Montigny le Bretonneux, France); 
recombinant human Hsp60 was acquired from Tebu-Bio (Tebu-Bio, Megenta, 
Italy). Proteomic grade trypsin was from Promega (Promega, Milano, Italy), 
Compounds 1-7 were synthesized as reported elsewhere (Rosselli S. et al., 
2007); compounds 8 and 9 were selected from those present in the natural 
compound library of the Department of Pharmacy of the University of 
Salerno. Purification and structural characterization of these compounds were 
previously published (Dal Piaz F. et al. 2007; Dal Piaz F. et al. 2013). 
 
2.10 Chemical proteomics 
In order to perform chemical proteomic experiments, SR2017 (1.1 mg) was 
incubated at 30 °C with 8.5 mg of an epoxy-activated sepharose resin 6B 
(Sigma-Aldrich) in 500 µl of 30 mM NaHCO3, 40% (v/v) CH3CN (pH 8), to 
achieve compound immobilization. The reaction was monitored by LC/MS 
using a LC-Q Advantage instrument coupled with a Accela HPLC system 
(Thermo Fisher Scientific). Reaction was completed after 4 h, leading to a 
SR2017 concentration of about 10 mmol for 1 ml of resin. Un-reacted resin 
epoxy groups were deactivated by adding 50 µl of 1 M ethanolamine. Control 
resin was prepared directly incubating 8.5 mg of a epoxy-activated sepharose 
resin 6B with 1 M ethanolamine.  
Jurkat (human leukemia, T cell lines) obtained from American Type Cell 
Culture (ATCC, Sesto San Giovanni, Italy), were maintained in RPMI 1640 
medium supplemented with 10 % (v/v) Fetal Bovine Serum (FBS), 2 mM l-
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glutamine and antibiotics at 37 °C in humidified 5 % CO2 atmosphere. To 
ensure logarithmic growth, cells were sub-cultured every 2 days. All 
experiments were performed using cells at 2x10
5
 cells/ml density. Under given 
experimental conditions, untreated cells were able to double in number in less 
than 24 hr. For protein extracts, control or treated cells were harvested by 
using a solution of trypsin-EDTA and washed three times with phosphate 
buffer saline (PBS). Cells were collected by centrifugation for 10 min at 400 g 
and lysed for 30 min on ice in PBS containing 0.1 % Igepal (lysis buffer) and a 
protease and phosphatase inhibitor cocktail (P8340, Sigma-Aldrich, St. Louis, 
MO, USA). Samples were clarified by centrifugation for 15 min at 15000 g at 
4 °C. Protein concentration was determined by Bio-Rad DC Protein Assay 
(Bio-Rad, Hercules, CA, USA) using bovine serum albumin as a standard. 
Jurkat cell lysates (500 µg) were incubated with SR2017 loaded or with 
control resin. The beads were washed three times with lysis buffer and then 
three times with PBS. Interacting proteins were eluted by 50 µl of Laemmli 
buffer (60 mM Tris HCl pH 6.8, 2 % sodium dodecylsulfate, 10 % glycerol, 
0.01 % blue bromophenol, 5 % β-mercaptoethanol). Eluted proteins were 
separated on a mono-dimensional 12 % SDS-PAGE and stained with Brilliant 
Blue G-Colloidal (Sigma-Aldrich). Each gel line was cut in 10 pieces, reduced 
by DTT, alkylated using iodoacetamide, and digested by trypsin. The resulting 
fragments were extracted and analyzed by LC/MS/MS using a LTQ Orbitrap 
XL ESI-mass spectrometer (Thermo Fisher Scientific) equipped with a nano-
ESI source, coupled with a nano-Aquity capillary UPLC (Waters): peptides 
separation was performed on a capillary BEH C18 column (0.075 mm × 100 
mm, 1.7 µm, Waters) using aqueous 0.1% formic acid (A) and CH3CN 
containing 0.1% formic acid (B) as mobile phases. Peptides were eluted by 
means of a linear gradient from 10 % to 4 0% of B in 45 min and a 300 
nl•min-1 flow rate. Peptide fragmentation was achieved using helium as 
collision gas and a collision cell energy of 30 eV. Mass spectra were acquired 
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in a m/z range from 400 to 1800, and MS/MS spectra in a m/z range from 25-
2000. MS and MS/MS data were used by Mascot (Matrix Science) to 
interrogate the Swiss Prot non-redundant protein database. Settings were as 
follows: mass accuracy window for parent ion, 10 ppm; mass accuracy 
window for fragment ions, 50 millimass units; fixed modification, 
carbamidomethylation of cysteines; variable modifications, oxidation of 
methionine. Proteins with scores > 65 and identified by at least 2 significant 
sequences, were considered as reliable proteins.  
 
2.11 Surface plasmon resonance (SPR) 
SPR analyses were carried out on a BIACORE 3000 instrument (GE-
Healthcare) according to our previously published procedures (Dal Piaz F. et 
al. 2009; Dal Piaz F. et al. 2010). Briefly, PARPγ and HSP60 surfaces were 
prepared on a research−grade CM5 sensor chips (GE Healthcare). Proteins 
(100 µg•ml-1 in 10 mM CH3COONa, pH 5.0) were immobilized using a 
standard amine−coupling protocol, to obtain densities of 3–5 kRU (1000 RU 
corresponds to the binding of ~ 1 ng per square mm of protein on the dextran 
surface). Testing compounds were dissolved in 100 % DMSO to obtain 4 mM 
solutions, and then diluted in PBS (10 mM NaH2PO4, 137 mM NaCl, 2.7 mM 
KCl pH 7.4) containing variable amounts of DMSO, in order to achieve a final 
DMSO concentration of 0.1 %. For each molecule a six−point concentration 
series spanning 0.025–1 µM was set up. SPR experiments were carried out at 
25 °C, with a 50 µl•min-1 flow rate. Association and dissociation times were 
set at 60 s and 300 s, respectively. Simple interactions were adequately fit to a 
single−site bimolecular interaction model to yield KD. BIAevaluation 
software (GE Healthcare) was used for sensorgrams elaboration. Same 




2.12 PARPγ/LBD peptide mapping 
PARPγ was incubated with a 2:1 molar excess of SR2017 under stirring for 15 
min in PBS at 37 °C. To eliminate the un-reacted diterpene, reaction mixtures 
were loaded on a GELoader micropipette tips (Eppendorf, Milano, Italy) 
packed with Poros R2 (Perseptive Biosystems, Firmingam, MA, USA) 
reversed phase materials. Eluted proteins were loaded on a mono-dimensional 
12% SDS-PAGE, stained with Brilliant Blue G-Colloidal, reduced, and 
digested by trypsin. The resulting fragments were extracted and analyzed by 
LC/MS/MS as described above. 
 
2.13 Computational chemistry 
Molecular modeling and graphics manipulations were performed using 
Maestro (Maestro, version 10.1, Schrödinger, LLC, New York, NY, 2015) and 
UCSF-Chimera 1.8.1 software packages (Huang C.C. et al. 1996) running on a 
E4 Computer Engineering E1080 workstation provided of a Intel Core i7-930 
Quad-Core processor. CovDock algorithm (Zhu K. et al. 2014) of the 
Schrodinger Small Molecule Drug Discovery Suite was used for all docking 
calculations. Figures were generated using Pymol 1.0 (Warren L. DeLano 
"The PyMOL Molecular Graphics System." DeLano Scientific LLC, San 
Carlos, CA, USA. http://www.pymol.org/). 
 
2.13.1 Protein and Ligand Preparation 
The crystal structure of PPARγ in complex with ligand LT175 (PDB code: 
3B3K) (Montanari R. et al. 2008) was download from the PDB Bank (Berman 
H.M. et al. 2002) and employed for the automated docking studies. The 
protein was processed through the Protein Preparation Wizard in Maestro 
(Sastry G.M. et al. 2013). The right bond orders as well as charges and atom 
types were assigned and the hydrogen atoms were added to protein. Arginine 
and lysine side chains were considered as cationic at the guanidine and 
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ammonium groups, and the aspartic and glutamic residues were considered as 
anionic at the carboxylate groups. All crystallographic water molecules were 
deleted. Imidazole rings of H449 and H323 into PPARγ were set in their Nτ 2-
H (N tau-H) tautomeric state. Moreover, an exhaustive sampling of the 
orientations of groups, whose H-bonding network needs to be optimized, was 
performed. Finally, the protein structures were refined with a restrained 
minimization with the OPLS2005 force field (Song Z. et al. 2000) by 
imposing a 0.3 Å root-mean-square deviation (rmsd) limit as the constraint.  
The core structure of SR2017 was retrieved from the Cambridge Structural 
Database (CSD) (Allen F.H. 2002) (CSD refcode: YALXIU) and modified 
with the fragment dictionary of Maestro. The ligand was then preprocessed 
with  LigPrep 3.3 (LigPrep, version 3.3, Schrödinger, LLC, New York, NY, 
2015) and optimized by Macromodel 10.7 (MacroModel, version 10.7, 
Schrödinger, LLC, New York, NY, 2015) using the MMFFs force field with 
the steepest descent (1000 steps) followed by truncated Newton conjugate 
gradient (500 steps) methods. Partial atomic charges were computed using the 
OPLS-AA force field.  
 
2.13.2 Docking Simulations 
Docking of SR2017 to PPARγ was performed with the CovDock algorithm, 
which comprises three main stages: first, conventional noncovalent docking of 
the prereactive species into the alanine mutated form of the receptor, on the 
basis of the rapid sampling provided by Glide (Friesner R.A. et al. 2004; 
Halgren T.A. et al., 2004; Friesner R.A. et al. 2006). Then, the residue is 
mutated back to its original chemical structure and its side chain conformation 
is sampled with a rotamer library, in order to find a state consistent with 
covalent bond formation. The covalent bond parameters are taken from the 
OPLS force field, such that any nonphysical bond distances, angles, or 
torsions will be appropriately penalized. Finally, refinement of the covalently 
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bound protein−ligand complex, followed by selection of optimal structures 
with program Prime (Jacobson M.P. et al. 2004; Jacobson M.P. et al. 2002). 
The resultant protein-ligand geometries are ranked based on VSGB 2.0, an all-
atom energy function based on OPLS force field and Generalized Born 
solvation model (Li J. et al. 2011). As input, we specified Michael’s addition 
as the type of reaction by which the ligand binds to the receptor. The reaction 
is predefined to recognize the ligand reactive group with the encoded 
SMARTS pattern (in this case the α,β-unsaturated carbonyl moiety present in 
SR2017), and to perform the postreaction changes in hybridization of the 
ligand. In the receptor section, the sulfhydryl group Cys285 side chain of 
PPARγ was selected as the reactive residue. 5 output poses were generated. 
The top one pose, based on its Prime energy property, was selected and is 
presented in Figure 10. The reaction generated a chiral center at position 16 in 
the (R)-configuration. 
 
2.14 Plasmids and transient transfection experiments 
The recipient cells used for transfection experiments were HEK293T cells that 
stably express an exogenous Flag-tagged PPARγ from a transfected PCDNA-3 
vector carrying a complete PPARγ cDNA. The PPRE-Luc plasmid contains a 
luciferase reporter gene under the transcriptional control of three copies of the 
PPRE (Peroxisome Proliferator Response Element) derived from Acyl-CoA 
oxidase gene fused upstream to the herpes simplex thymidine kinase (TK) 
promoter. The RSV-Gal plasmid, expressing -galactosidase gene driven by the 
strong Rous Sarcoma Virus (RSV) promoter/cassette was used as an internal 
control for transfection efficiency. The day before transfection, the Flag-
PPARγ-HEK293 cells were plated in 12-well plates to reach 70% confluence. 
After 24 hr, the growth medium was replaced with OPTI-MEMI without 
serum and antibiotics and cells transfected with the luciferase reporter gene 
(PPRE-Luc) using lipofectamine 2000 reagent according to manufacturer’s 
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instructions. Ten-twelve hours after transfection, cells were washed and 
treated with different concentrations of rosiglitazone and SR2017. The wild-
type and mutant PPARγ1 containing expression vectors were kindly provided 
by Dott. Takuma Shiraki. The mutant receptor carries an Alanine that replaces 
a Cysteine residue at position 285 (C285A). The experiments were carried out 
as above into basal HEK293T cells and also in these cases the RSV--Gal 
plasmid was used as control for transfection efficiency. At least three 
independent experiments were performed for each transfection carried out in 
duplicate. Luciferase activity was normalized to -galactosidase activity and 
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3.1 Oridonin: insight its multifunctional effects 
Oridonin (7,20-epoxy-ent-kauranes), a diterpenoid isolated from the medicinal 
herb Rabdosia rubescens (Hemsl.) H. Hara (Figure 1), was firstly identified in 
the1967 (Fujita E. et al. 1967) and subsequently synthesized in the 1973 









Fig.1: Chemical structure of oridonin 
 
This compound has been shown to have multiple biological activity; in fact it 
has been used in Chinese medicine to treat several diseases. It has aroused 
high interest especially in cancer researchers due its potential to be developed 
into tumor chemotherapeutic drug (Sartippour M.R. et al. 2005). About its 
structural requirements for its anticancer activity it is reported that the α-
methylene cyclopentanone of the chemical structure of oridonin, is the 
pharmacophore of this molecule. In fact, changes in this portion of the 
molecule (e.g., split ring or saturated methylene) significantly affect its 
anticancer activity (Fujita E. et al. 1967). Besides, also the presence of a 
hydrogen bond between the hydroxyl group at C-6 and the carbonyl group at 
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C-15 plays an important role for oridonin activity; inducing a partial positive 
polarization at C-17, thus increasing its susceptibility to nucelofilic attack 
(Node M. et al. 1983). 
The ability of oridonin to inhibit tumor cell growth either in in vitro or in vivo 
experimental models has indeed been repeatedly confirmed by many research 
groups. Inhibition of tumor cell growth by oridonin was ascribed to the ability 
of the drug to affect cell cycle progression and/or to promote cell death by 
apoptosis and autophagy. Several studies indicated that oridonin inhibits cell 
cycle progression and then cell growth and proliferation in a variety of human 
cancer cell lines, including those from the breast, lung, and prostate (Ikezoe T. 
et al. 2003). However, flow cytometric analysis revealed that oridonin elicited 
a G1/S block in several cell lines, and an S-G2/M arrest in other ones. These 
blocks are produced by modulating the expression/activity of different cell 
cycle regulatory proteins. Specifically, it has been shown that oridonin can 
affect cell cycle progression by regulating a series of essential cell cycle-
related proteins such as cdc2, cdc25c, cyclinB, p53 and p21 (Ikezoe T. et al., 
2003). 
In many cancer cell lines oridonin is also able to induce apoptosis. There are 
two major pathways of apoptosis: the death-receptor pathway, which is 
mediated by the activation of death receptors, and the mitochondrial pathway, 
which is mediated by noxious stimuli that ultimately lead to mitochondrial 
injury. Again, depending on the cell type and the experimental conditions 
used, oridonin has been shown to modulate the expression of proteins 
implicated in either death receptor-mediated (i.e. FAS, FAS ligand) (Liu Y.Q. 
et al. 2006) or mitochondria-dependent apoptotic pathways (i.e. increased 
BAX/Bcl2 ratio (Zhang C. et al. 2004). Therefore, oridonin-induced apoptosis 
occurs via a variety of mechanisms. Evidences showed that oridonin induces 
apoptosis through both extrinsic and intrinsic pathways, since a large number 
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of proteins interfering with these pathways into the cell were modulated by 
oridonin (Zhang TM. 1982). 
In recent years, in addition to the pro-apoptotic ability of oridonin, it was 
being increasingly highlighted its ability to induce autophagy in some cancer 
cells. Distinct from apoptosis, autophagy (an evolutionarily conserved, multi-
step lysosomal degradation process in which a cell destroys long-lived 
proteins and damaged organelles) may play crucial regulatory roles in many 
pathological processes, most notably in cancer. Recent studies showed that 
oridonin induced HeLa cell autophagy. In fact, oridonin was reported to 
negatively modulate several pro-survival signaling proteins, such as NF-kB, 
MAPKs and PI3K/Akt. 
Besides the aforementioned anti-tumor properties in vitro, oridonin has been 
demonstrated to bear remarkable anti-neoplastic activities in vivo. It 
suppressed proliferation of different cell lines in mice (Zhu Y. et al. 2007; Gao 
F.H. et al. 2010), induced typical mitochondrial apoptosis in acute myeloid 
leukemic (AML) cells, and exhibited substantial anti-leukemia activities with 
negligible side-effects in murine models (Zhou G. B, et al. 2007 a,b). 
Moreover, oridonin possessed high stability under different conditions: it was 
observed to be over 99% of the nominal concentrations after storage at −20 ◦C 
for 30 days and 4 ◦C for 7 days, respectively (Mei Y. et al. 2008). 
In summary, oridonin may become an effective anti-tumor agent due to its 
versatile anti-proliferative capabilities including regulating cell cycle, 
apoptosis and autophagy, but more studies are necessary to elucidate better its 
mechanism of action. 
 
3.2 Aims of the project 
Recently, our research group identified and validated the possible targets of 
this molecule by chemical proteomic approach (Dal Piaz F. et al. 2013). In 
particular, we provided evidences that oridonin is able to directly bind the 
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multifunctional, stress-inducible heat shock protein 70 1A (HSP70). Although 
the identification of HSP70 as a molecular target of this molecule suggested a 
mechanism of action of oridonin consistent with the multiple biological 
activities described for this diterpene, a large number of proteins and then 
pathway are affected by the treatment of cells with this molecule (Zhang T.M. 
1982; Ikezoe T. et al., 2003). Then, it’s obvious to think that oridonin is able 
to bind more than one target in cell and give several biological effects.  
Moreover, we decided to study this molecule again in order to overcome the 
limitations of the technique used before. More in details, the study of the 
possible interactors of a biological small molecule can be carried out with 
different methods, but affinity chromatography remains the most widely used 
method. Like any other technology, chemical proteomic has strengths and 
weakness that require careful consideration up front. The primary limitation of 
affinity chromatography is the need to derivatize the small molecule of 
interest. Unfortunately, many small molecules cannot be modified without 
affecting their bioactivity, and presumably binding. Furthermore, this 
approaches are performed using cell lysates, but it is important to keep in mind 
that the lysis method generally used dose not capture all proteins equally well 
and that it’s difficult to evaluate which proteins are missing from the 
respective lysate preparation (e.g. membrane proteins). On the other hand, 
some proteins are simply so abundant or prone to interacting generically with 
either hydrophobic or charged surfaces that they create a high background 
level (Rix U & Superti-Furga G. 2008). A further problem is the accurate 
identification of proteins interacting with the molecule covalently immobilized 
on a solid support. Therefore, affinity chromatography of small molecules is 
severely limited due to the vast structural diversity and complexity of 
biologically active small molecules thus resulting a method that cannot be 
universally applied to the target identification of a studied small molecule. 
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Given the shortcomings of current target identification methodologies, we 
decided to use another and orthogonal approach to define the partners of 
oridonin, called with acronym DARTS (Drug Affinity Responsive Target 
Stability). Such approach could potentially identify any protein targets of 
small molecules with no limitations posed by chemistry or mechanism of 
action. In fact, DARTS is a general methodology for identifying and studying 
protein-ligand interactions. The idea that a small molecule drug would 
stabilize its target protein’s structure and result in protease resistance offers a 
possible solution to the problem of target identification, so long as the 
decreased proteolysis could be readily detected in complex samples. This 
enhanced stability is postulated to result from a shift in the thermodynamic 
landscape of the protein to favor the ligand-bound state, which prevents much 
of the protein’s innate flexibility and movement from being realized. It is 
similar to affinity chromatography in that both are affinity-based methods that 
start with complex protein samples and selectively enrich the target protein(s) 
while depleting all non-target proteins. However, whereas affinity 
chromatography utilizes positive enrichment by selectively pulling out the 
target proteins and leaving behind non-targets, DARTS uses negative 
enrichment by digesting away non-target proteins, while leaving behind the 
target proteins that are rendered protease-resistant. Therefore, DARTS is 
particularly useful for the initial identification of the protein targets of small 
molecules, but can also be used to validate potential protein-ligand interactions 
predicted or identified by other means and to estimate the affinity of 
interactions. Finally, this approach is simple and advantageous because it can 
be performed using crude cell lysates and other complex protein mixtures 
(without requiring purified proteins), and uses native, unmodified small 











Fig 2: Theoretical model and basic strategy of DARTS. 
Adopted from Lomenick B et al. 2009 
 
Thus, with the final aim of expanding and validate our knowledge about the 
mechanism of action of this molecule, also seen the limitations of the used 
chemical proteomic approach mentioned before, we decided to use this 
method of identification of possible targets. 
Finally, we selected a set of experiments to validate targets and understand the 
role of oridonin in cell. 
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Results and discussion 
 
3.3 Synthesis and characterization of fluorescent oridonin companion 
imaging drug 
The knowledge of pharmacokinetics and pharmacodynamics parameters of 
drugs in live cells could lead to a better understanding of their mechanism of 
action. Approaches currently used to this aim require tissue/cells lysis or rely 
on indirect assays and thus often provide an incomplete view of drugs fate and 
metabolism. In this project, in order to provide more detailed information 
about the mechanism of action of oridonin inside the cells and to get 
experimental conditions for the further studies, firstly, we synthesized its 
fluorescent derivate. Using a fluorescence microscopy based technique, it was 
possible to measure drug uptake and to get the map drug-target interaction in 
real time at subcellular resolution. In particular, this approach enabled high-
resolution spatial and temporal mapping of drug distribution inside the cancer 
cell and led us to put the basis for the subsequent experiments. 
The fluorescence microscopy is generally applicable to fluorescently labeled 
drugs; in our experiments BODIPY FL was chosen as fluorescent tool since its 
chemical features are useful probe for intracellular assays. In particular, (i) 
BODIPY is relatively non-polar with the chromophore presenting electrical 
neutrality, therefore minimizing perturbation to the modified drug; (ii) it has a 
relatively long lifetime (lifetime about 4.0 ns); (iii) it’s highly permeant to live 
cells, easily passing through the plasma membrane, where it accumulates over 
time (Dubach J.M. & Vinegoni C. 2014). 
To develop fluorescent oridonin companion imaging drug (CID), two different 
final modified versions of the drug were chose. On the basis of literature data 
showing that the hydroxyl group at position C-1 is not essential for the 
cytotoxic activity of oridonin (Wenjing Z. et al. 2010), this group was selected 
as point of attachment of the dye. We first synthesized the esterification 
59 
 
version of oridonin, but this derivate resulted not stable in our experimental 
conditions. Therefore, we produce the carbamate version of oridonin, using the 
synthetic scheme reported in Figure 3. 
 
 
Fig.3: Synthetic route for oridonin-BODIPY FL (compound 4) 
 
Before using the fluorescent version of oridonin for our study, it was 
mandatory to verify if the chemical modification caused significant effects of 
its biological activity. To that aim, Jurkat cell proliferation inhibition potential 
of this CID to that of unmodified oridonin was compared: exponentially 
growing cultures of Jurkat (T-cell leukemia) cells were exposed to increasing 
concentrations of both drugs and cell viability was evaluated after 24 h and 
48h of treatment. Achieved results (Figure 4) demonstrated that, under our 
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experimental conditions, the two molecules had similar antiproliferative 
activities. 
Fig. 4: Comparison of tumor cell growth inhibition activity of modified and unmodified 
oridonin. Values of IC50 for oridonin was 1.25µM and 1 µM for 24h and 48h; IC50 for oridonin 
BODIPY FL was 1.2µM and 0.66 µM for 24h and 48h. 
 
Given the known ability of oridonin to covalently interact with HSP70 (Dal 
Piaz F. et al. 2013), we evaluated if also the imaging drug retains this skill. 
Therefore, we incubated HSP70 with different concentrations of CID for 15 
min and samples by SDS-PAGE experiment were resolved. Fluorescence 
intensity was analyzed and a dose dependent covalent binding of CID to the 






Fig.5: Denaturing gel electrophoresis of increasing concentration of oridonin BODIPY FL 
incubated with purified HSP70 for 15 min and imaged with a fluorescence gel scanner using 
488 nm excitation/512 nm emission. Note the dose dependent covalent binding of oridonin 
BODIPY FL to HSP70 
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Finally, the stability of fluorescent oridonin in our experimental conditions 
was studied. The lifetime of CID at different pH and incubation times was 






Fig.6: Lifetimes of CID in different buffer solutions for different indicated time points 
 
Achieved results (Figure 6) demonstrated that this molecule was stable for 24h 
in almost all the tested conditions, unless in 2-(N-morpholino)ethanesulfonic 
acid (MES) buffer, due to the reactivity of carbamate function in acid 
conditions. 
All together, these data indicated this new CID as a hopeful probe for imaging 
experiments to investigate the mechanism of action of oridonin. 
 
3.4 Oridonin uptake in live cells 
In order to evaluate the kinetic of oridonin penetration into the cells, Jurkat 
cells were treated with a CID concentration corresponding to its IC50. Real-
time in vitro measurements (Figure 7) showed that the amount of modified 
oridonin within the cells increased at 1 h and reached its maximum after 2 h of 
incubation time and after 3h it started decreasing. The drug accumulated both 




Fig.7: Imaging of Jurkat cells to determinate the uptake of oridonin BODIPY FL in cell. 
Green signal: oridonin BODIPY FL. Scale bar: 20µm. 
 
Moreover, the cellular localization of oridonin in Jurkat cells after a long 
washing time was investigated. Jurkat cells were first treated with the CID and 
then washed for different times (from 1h up to 3h). As reported in Figure 8, 
also after 2h of treatment and 3h of washing, fluorescent oridonin was still 
within cytoplasm and nuclei. This long persistence of oridonin into the cells 
could be due to a covalent stabilization of the interaction of oridonin with its 
protein targets. 
 
Fig.8: Real time imaging of Jurkat cells following 2h of incubation of oridonin BODIPY FL 
and different washing times. Green signal: oridonin BODIPY F; Blue signal: Hoechst 33342. 
Scale bar: 20µm 
 
3.5 Optimization of DARTS protocol  
Once set the experimental conditions for the cell treatment with oridonin, we 
moved to proteomic studies in order to identify the putative molecular targets 
of this diterpene. In particular, we carried out a proteomic-based study, using a 
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DARTS approach. This method is useful for the identification and to study 
protein-small molecule interactions. 
As first step, we optimized enzymatic digestion conditions, selecting the better 
proteolytic agent, and the amount of enzyme to be used. There are different 
proteases that could be used for DARTS, in our experiments subtilisin was 
selected because we needed a rapid kinetic of hydrolysis and a protease with a 
broad specificity; in fact, protein lysates are highly heterogeneous mixture of 
proteins with diverse physiochemical properties, including native and 
denatured proteins. Thermolysin, another enzyme widely used for this 
technique, it is not very stable and there is a significant proportion of the 
proteome that is not highly resistant to its proteolytic activity (Lomenick B. et 
al. 2009). 
A wide range of subtilisin concentrations were tested to define the best ratio of 
proteins/protease, using 30 min as experimental time. The obtained results 









Fig.9: Optimization of DARTS protocol. Lysates from untreated human Jurkat cells were 
incubated with DMSO for 1h at room temperature. Each sample was then split into seven 
aliquots that underwent digestion with various concentrations of subtilisin, relative to the total 
amount of protein per sample, for 30 min at room temperature. Digestion was stopped by 
adding sample loading buffer and boiling immediately. Each sample was then loaded onto 
10% SDS/PAGE gels and stained with Brilliant Blue G-Colloidal. 
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The next step was to verify if the enzyme activity was somehow altered by the 
presence of oridonin. Hence, we incubated Bovin Serum Albumin (BSA) in 
presence or in absence of oridonin and the resulting proteolytic pattern was 
then studied, to investigate if the presence of oridonin protected BSA by 







Fig.10: Subtilisin activity is unaffected by oridonin under identical experimental conditions 
except with BSA as a non-binder control. 
 
The obtained results showed that oridonin did not interfere with the proteolytic 
activity of the enzyme. 
 
3.6 Identification of molecular targets for oridonin using DARTS 
We used DARTS to discover new possible oridonin targets and to validate 
those previously identified. Jurkat cells were used to perform all the 
experiments, since oridonin/HSP70 complex formation was previously 
demonstrated in this leukemia-derived cell line (Dal Piaz F. et al. 2013). Thus, 
whole cell lysates from Jurkat cells were exposed to 20 μM oridonin for 1 h at 
R.T. and then digested with subtilisn. We decided to use a dose higher than 
IC50 (reported before) to enhance the possibility to detect oridonin-complexes: 
generally, any small molecule believed to bind proteins should be suitable for 
DARTS, but the concentration ranges of small molecule to use is also an 
important variable. Given that the targets of most small molecules usually are 
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unknown also the binding affinities will be unknown. Therefore, a high 
concentration than IC50 of oridonin to ensure saturation of the protein targets to 
obtain the oridonin putative targets was used. For this experiment, three 
different samples were analyzed: 1) the whole lysate without digestion 2) the 
digested lysate incubated with oridonin 3) and the digested lysate without 
oridonin; this last control was a negative control required to discriminate 
between proteins specifically interacting with the diterpene and unspecific 
background. Examination and comparison of the lanes in DARTS experiment 







Fig.11: DARTS using whole Jurkat cell-lysate: lane1) lysate treated with Oridonin 20µM and 
then digested for 30 min with subtilisin; lane2) lysate treated with DMSO and then digested 
with subtilisin; lane3) whole Jurkat cell lysate as control. Note the presence of three protected 
bands in oridonin treated sample than digested control 
 
These bands and the corresponding gel regions of the control lane were 
subjected to a classical in situ gel-digestion, followed by mass spectrometry 
analysis; this procedure allowed us to identify different proteins enhanced in 
the oridonin-treated sample. DARTS experiments were performed in triplicate 







Table 1: Mass spectrometry identified proteins of DARTS experiment on whole cell-lysate 




TLN1_HUMAN Talin-1 OS=Homo sapiens GN=TLN1 PE=1 SV=3 271766 17 297
SF3B3_HUMAN Splicing factor 3B subunit 3 OS=Homo sapiens GN=SF3B3 PE=1 SV=4 136575 11 175
IMB1_HUMAN Importin subunit beta-1 OS=Homo sapiens GN=KPNB1 PE=1 SV=2 98420 10 338
ILF3_HUMAN Interleukin enhancer-binding factor 3 OS=Homo sapiens GN=ILF3 PE=1 SV=3 95678 11 145
NUP93_HUMAN Nuclear pore complex protein Nup93 OS=Homo sapiens GN=NUP93 PE=1 SV=2 93943 5 93
ENPL_HUMAN Endoplasmin OS=Homo sapiens GN=HSP90B1 PE=1 SV=1 92696 12 197
HS90B_HUMAN Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=4 83554 36 2633
NUCL_HUMAN Nucleolin OS=Homo sapiens GN=NCL PE=1 SV=3 76625 18 1977
HSP7C_HUMAN Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1 SV=1 71082 21 2005
GRP75_HUMAN Stress-70 protein, mitochondrial OS=Homo sapiens GN=HSPA9 PE=1 SV=2 73920 6 144
XRCC6_HUMAN X-ray repair cross-complementing protein 6 OS=Homo sapiens GN=XRCC6 PE=1 SV=270084 17 664
CALX_HUMAN Calnexin OS=Homo sapiens GN=CANX PE=1 SV=2 67982 16 358
* values represent the mean of three indipendent results  
 
This study led to the identification of several putative oridonin targets; in 
particular, once again, we found HSP70 as target of oridonin, thus confirming 
the efficacy of DARTS approach for our purpose. 
The next step was to study the targets identified on the lysate into the cell. The 
lysate is a good starting point to define the interactome of a small molecule but 
is a very simple model that differs from the real condition in cell; performing a 
study on live cells also the effects of active metabolism and the cellular 
compartmentalization are taken into account. Therefore, Jurkat cells were 
treated with two different concentrations of oridonin (10μM and 20μM) for 2 
hours. The incubation time of our in cells experiment was selected on the basis 
of results obtained previously. Cells were lysate and their extracts were 
subjected to subtilisin digestion; a comparison between electrophoretic 
analysis of digestion mixture from lysates of treated and untreated cells 
revealed, the presence of a protected band (Figure 12). MS-spectrometer 
analysis of mixture of peptides of this band confirmed again HSP70, 
confirming once again that also inside the cells oridonin efficiently interacts 











Fig.12: DARTS approach using intact Jurkat cells: lane1) cells treated with Oridonin 20µM 
for 2h of incubation time and then digested; lane2) cells treated with Oridonin 10µM for 2h of 
incubation time and then digested; lane3) cells treated with DMSO for 2h of incubation time 
and then digested; lane4) whole Jurkat cells as control. 
 
Table 2: Mass spectrometry identified proteins of DARTS experiment on intact Jurkat cell 




HS90B_HUMAN Heat shock protein HSP 90-beta OS=Homo sapiens GN=HSP90AB1 PE=1 SV=4 83554 6 201
NUCL_HUMAN Nucleolin OS=Homo sapiens GN=NCL PE=1 SV=3 76625 9 459
HSP7C_HUMAN Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1 SV=1 71082 11 560
TCPG_HUMAN T-complex protein 1 subunit gamma OS=Homo sapiens GN=CCT3 PE=1 SV=4 61066 13 350
CH60_HUMAN 60 kDa heat shock protein, mitochondrial OS=Homo sapiens GN=HSPD1 PE=1 SV=2 61187 2 58
TCPA_HUMAN T-complex protein 1 subunit alpha OS=Homo sapiens GN=TCP1 PE=1 SV=1 60819 4 72
HNRPK_HUMAN Heterogeneous nuclear ribonucleoprotein K OS=Homo sapiens GN=HNRNPK PE=1 SV=1 51230 4 142
* values represent the mean of three indipendent results  
 
3.6.1 Validation of selectivity of oridonin towards identified molecular 
targets using DARTS approach 
The specificity of the putative oridonin targets was tested performing the same 
DARTS approach using another diterpene, nervosanin B, as possible negative 
control. This molecule was selected since its structure is very close to that of 
oridonin (Figure 13) (Wenjing Z. et al. 2010) but it shows none or weak 
cytotoxicity against several cancer cell lines (IC50 on Jurkat cells after 24h was 
more than 50 µM). Besides, nervosanin B is a well-known Isodon rubescence 
kaurane diterpene present in our laboratory library. Thus, DARTS procedure 
was applied on Jurkat lysate using nervosanin B at 20µM. The obtained results 
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Fig.13: A) Structure of Nervosanin B; B) DARTS approaches on Jurkat lysate: lane 1) Jurkat 
lysate as control; lane2) Jurkat lysate incubated with DMSO for 1h and then digested with 
subtilisin; lane3) Jurkat lysate following 1h of incubation time with nervosanin B at 20µM and 
then digested with subtilisin. 
 
3.6.2 Western Blot analysis to validate some of the molecular targets of 
oridonin 
To confirm the results achieved by DARTS MS-based approaches, we 
performed DARTS on Jurkat lysates using western blot analysis. In particular, 
we focused our attention on proteins previously identified by the MS-based 
approach, whose activity could be related to the oridonin treatment effects.  
Therefore, the investigated proteins were: NCL (Nucleolin), HSP70, PPARγ 
(Peroxisome proliferator-activated receptor gamma), HSP90 (Heat shock 
protein HSP 90), Trx (Thioredoxin), TrxR (Thioredoxin Reductase) and 
finally GAPDH (Glyceraldehyde-3- phosphate dehydrogenase); this last 
protein was selected as loading indicator, since it is reported to be more 










Fig.14: Validation by western blotting of LC-MS identified proteins from DARTS 
experiments. Protein lysate from untreated Jurkat cells and protein lysates from Jurkat cells 
digested with subtilisin in presence and in absence of oridonin and nervosanin B were 
separated on SDS-PAGE and followed by immunoblotting with antibodies against GAPDH, 
HSP90, HSP70, TRX, TRXR, NCL, PPARγ. 
 
As we expected, the proteins that specifically interacted with oridonin were 
protected from digestion with subtilisin and in the resulting blotting more 
marked bands corresponding to them were observed (Figure 14). 
 
3.7 “Complementary” chemical proteomic approach: affinity purification 
and mass spectrometry analysis of oridonin partners 
With the aim of expanding and validate the knowledges about target(s) of 
oridonin, an additional orthogonal chemical proteomics approach was applied. 
In literature is largely reported that α-β unsatured carbonyl group is 
responsible for oridonin and related compounds biological activity and targets 
interactions, herein we decided to also study the contribution of A-B-C rings 
subtitutions on the oridonin bioactivity. In fact, it is well known that in order 
to stabilized interaction and molecular recognition of a small molecule and the 
physiological ligand, the main pharmacophore is not the only active part of the 
molecule important for it, but it’s very important also the whole skeleton of 
the molecule for the interaction stabilization. Given the highly functionalized 
chemical structure of this molecule, we tried to define also, the possible 
protein partners of this part of the molecule. In particular, using this approach 
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we tried to emphasize non covalent binders of oridonin. Therefore, a direct 
chemical proteomic approach was carried out using the α-β unsatured carbonyl 
group as point of attachment on a solid support (making it not available for 
possible interaction with targets). The experimental procedure we used was 
based on compound immobilized affinity chromatography and consisted in 
several steps (Figure 15). First, oridonin was anchored onto a solid support 
taking advantage of its electrophilic functional group, the α, β-unsaturated 
carbonyl group. The chemical immobilization of a small molecule ligand is 
usually achieved through suitable functional group and we used this 
functionality to achieve this purpose. In particular, a Tentagel resin was used 
as solid support and we evaluated reaction and the yield of the immobilization 
by HPLC. The functionalized resin was then incubated with Jurkat lysate. Cell 
extracts were also incubated with a free matrix, as a control experiment, to 
distinguish between specifically bound components and background 
contaminants. Finally, all the tightly bind proteins were eluted and the proteins 
from the negative control and from oridonin modified resin were identified by 












Fig.15: Workflow of “complementary chemical proteomic” on Jurkat lysate using oridonin: 
oridonin was conjugated to a specific solid support and the incubated with Jurkat cell lysate. 
Eluted proteins were resolved by SDS-PAGE experiment and after enzymatic digestion 
proteins were identified by LC-MS/MS 
 
The outcome of the Mascot database search (experiment was performed in 
triplicate) revealed the whole interactome of this immobilized oridonin. A list 
of identified proteins, from both gel lanes (control and matrix bearing 
oridonn), was obtained and compared to establish which proteins were 
specifically captured by oridonin. (Table 3). In this case, HSP70 was not found 
as a putative target; this result was not surprising since in this experiment the 
the α, β-unsaturated carbonyl group of oridonin was masked and our previous 
studies demonstrated that this group was critical for the interaction between 







Table 3: Mass spectrometry identified proteins of complementary chemical proteomic 
experiment 




NUCL_HUMAN Nucleolin OS=Homo sapiens GN=NCL PE=1 SV=3 76625 11 130
GRP78_HUMAN 78 kDa glucose-regulated protein OS=Homo sapiens GN=HSPA5 PE=1 SV=2 72333 4 81
PABP1_HUMAN Polyadenylate-binding protein 1 OS=Homo sapiens GN=PABPC1 PE=1 SV=2 70671 2 52
G6PI_HUMAN Glucose-6-phosphate isomerase OS=Homo sapiens GN=GPI PE=1 SV=4 63147 2 58
TCPA_HUMAN T-complex protein 1 subunit alpha OS=Homo sapiens GN=TCP1 PE=1 SV=1 60344 2 54
TCPH_HUMAN T-complex protein 1 subunit eta OS=Homo sapiens GN=CCT7 PE=1 SV=2 59367 2 51
KPYM_HUMAN Pyruvate kinase PKM OS=Homo sapiens GN=PKM PE=1 SV=4 58494 16 200
TCPD_HUMAN T-complex protein 1 subunit delta OS=Homo sapiens GN=CCT4 PE=1 SV=4 57924 2 51
ATPB_HUMAN ATP synthase subunit beta, mitochondrial OS=Homo sapiens GN=ATP5B PE=1 SV=3 56561 12 198
COR1A_HUMAN Coronin-1A OS=Homo sapiens GN=CORO1A PE=1 SV=4 51026 8 87
EF1G_HUMAN Elongation factor 1-gamma OS=Homo sapiens GN=EEF1G PE=1 SV=3 50119 4 77
HNRH1_HUMAN Heterogeneous nuclear ribonucleoprotein H OS=Homo sapiens GN=HNRNPH1 PE=1 SV=4 49229 9 155
HNRPF_HUMAN Heterogeneous nuclear ribonucleoprotein F OS=Homo sapiens GN=HNRNPF PE=1 SV=3 45672 12 145
PGK1_HUMAN Phosphoglycerate kinase 1 OS=Homo sapiens GN=PGK1 PE=1 SV=3 44615 19 330
HNRPD_HUMAN Heterogeneous nuclear ribonucleoprotein D0 OS=Homo sapiens GN=HNRNPD PE=1 SV=1 38434 10 89
MDHM_HUMAN Malate dehydrogenase, mitochondrial OS=Homo sapiens GN=MDH2 PE=1 SV=3 35503 13 132
RLA0_HUMAN 60S acidic ribosomal protein P0 OS=Homo sapiens GN=RPLP0 PE=1 SV=1 34274 4 60
RA1L2_HUMAN Heterogeneous nuclear ribonucleoprotein A1-like 2 OS=Homo sapiens GN=HNRNPA1L2 PE=2 SV=2 34225 7 89
RSSA_HUMAN 40S ribosomal protein SA OS=Homo sapiens GN=RPSA PE=1 SV=4 32854 6 72
1433E_HUMAN 14-3-3 protein epsilon OS=Homo sapiens GN=YWHAE PE=1 SV=1 29174 6 59
1433G_HUMAN 14-3-3 protein gamma OS=Homo sapiens GN=YWHAG PE=1 SV=2 28303 3 70
1433Z_HUMAN 14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 SV=1 27745 13 169
PSB1_HUMAN Proteasome subunit beta type-1 OS=Homo sapiens GN=PSMB1 PE=1 SV=2 26489 2 53
PSA5_HUMAN Proteasome subunit alpha type-5 OS=Homo sapiens GN=PSMA5 PE=1 SV=3 26411 2 55
EF1B_HUMAN Elongation factor 1-beta OS=Homo sapiens GN=EEF1B2 PE=1 SV=3 24764 2 54
RAN_HUMAN GTP-binding nuclear protein Ran OS=Homo sapiens GN=RAN PE=1 SV=3 24423 4 59
RS8_HUMAN 40S ribosomal protein S8 OS=Homo sapiens GN=RPS8 PE=1 SV=2 24205 2 54
GSTP1_HUMAN Glutathione S-transferase P OS=Homo sapiens GN=GSTP1 PE=1 SV=2 23356 11 178
RANG_HUMAN Ran-specific GTPase-activating protein OS=Homo sapiens GN=RANBP1 PE=1 SV=1 23316 2 50
RL18_HUMAN 60S ribosomal protein L18 OS=Homo sapiens GN=RPL18 PE=1 SV=2 21634 6 85
RAC2_HUMAN Ras-related C3 botulinum toxin substrate 2 OS=Homo sapiens GN=RAC2 PE=1 SV=1 21429 4 70
HBG2_HUMAN Hemoglobin subunit gamma-2 OS=Homo sapiens GN=HBG2 PE=1 SV=2 16126 2 62
* values represent the mean of three indipendent results  
 
The results achieved using the three chemical proteomics approaches (DARTS 
on cell lysates, DARTS on live cells and affinity-based chemical proteomics) 
were compared, leading to the Venn diagram reported in Figure 16. 
Interestingly, the only protein emerging in all the experiment as a possible 





Fig.16: Venn diagram of all experiments performed (DARTS on cell lysates, DARTS on live 




Recently, NCL has attracted the attention of many researchers as druggble 
molecule for many reasons. First of all, it’s a multifunctional protein present in 
many different cellular compartments and involved in many functions within 
the cells and each cellular pool of NCL can play a different role in cancer 
development (Berger C.M. et al. 2015). Moreover, the inhibition of this 
protein could explain better the complex biological activities of oridonin. 
Therefore, even if none of the proteins identified in our studies can be 
excluded a priori as a possible oridonin target, we performed an in-depth 
investigation on the biological role of oridonin in the interaction with 
nucleolin, through in vitro and in living cells assays. 
 
3.8 Characterization of physical interactions between oridonin and 
nucleolin 
The affinity of oridonin to nucleolin was evaluated by a Surface Plasmon 
Resonance (SPR)-based binding assay. SPR is an optical technique, based on 
the evanescent wave phenomenon, able to measure changes in refractive index 
onto a sensor surface, and it is suitable for characterizing macromolecular 
interactions. The binding between a compound in solution and its ligand 
immobilized on the sensor surface results in a change of the refractive index, 
that could be monitored in real time allowing the measurement of association 
and dissociation rates (Casper D. et al. 2004). 
The interaction is monitored in real time, and the amount of bound ligand and 
the rates of association and dissociation can be measured. Thus, NCL was 
immobilized on a CM5 sensor chip and oridonin was injected over at 
concentrations ranging from 0.001 to 0.5 μM. In Figure 17, the sensograms 
(association and dissociation SPR curves) obtained from the binding of 




Fig.17: Sensograms obtained from the binding of oridonin to nucleolin and nervosanin B and 
nucleolin at different concentrations (range of concentrations used from 0.001 to 0.5µM for 
each small molecule) 
 
As expected, the increase of response units (RU) in the association phase and 
the slope of the dissociation phase of the complex are clearly dependent on the 
analyte concentration. With the aid of a software (Biaevaluation software 3.0) 
it was possible measurement the dissociation constant of the complex and it 
was KD NCL/oridonin= 3.82 ± 1.2 nM. Moreover, we decided to check also the 
affinity of nervosanin B to NCL, as reported in Figure 17 there was no 
binding. 
 
3.9 Monitoring of nucleolin engagement by oridonin in live cells using 
CETSA assay 
In order to get more detailed information and evaluate oridonin and nucleolin 
interaction inside the cells we optimized and used Cellular Thermal Shift 
Assay (CETSA) experiment. CETSA, a recently published technique, allows 
to monitor and quantify the extent to which a drug candidate reaches and 
directly binds to a protein target of interest within a cell (Jafari R. et al. 2014). 
In particular, this approach offers the possibility to firmly link the observed 
phenotypic response to a compound with a particular target engagement. 
CETSA, provided by Molina and coworkers in 2013, relies on the principle of 
thermodynamic stabilization inferred to the protein as a result of ligand 
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binding, which can be used for the estimation of binding free energies as well 
other thermodynamic properties, for isolated systems at equilibrium (Jafari R. 
et al. 2014). Practically, the shift in thermal stability is estimated by measuring 
the amount of remaining soluble target protein at different temperatures for 
ligand treated and control samples. Briefly, CESTA protocol starts with the 
treatment of cells with either molecule of interest and vehicle as control, 
followed by heating of cells to denaturate and precipitate the protein of 
interest, cell lysis, removal of cell debris and aggregates through 
centrifugation, and finally detection of the remaining thermostabilized target 
protein by, e.g., denaturing gel electrophoresis and western blot detection 
using target-specific antibody (Figure 18). The apparent aggregation 
temperatures (Tagg) observed in the presence or in the absence of the drugs can 
be compared; the detection of substantial shifts as an effect of the presence of 
the drug demonstrate an effective ligand stabilization on the target protein. 
Therefore, a typical output form CESTA experiment is a comparison between 
apparent melting curves (or, more accurately, temperature-induced 
aggregation curves), in which the protein in the presence and absence of ligand 
is subjected to a panel of temperatures such that a potential thermal 
stabilization can be assessed. 
Alternatively, an isothermal dose-response fingerprints (ITDRFCETSA) is 
generated, in which the stabilization of the protein can be followed as a 
function of increasing ligand concentration. The latter requires knowledge of 













Fig.18: Schematic illustration of CETSA approach 
Adopted from Bradley W.D. et al., 2014 
 
In order to obtain information about the best Tagg to use for next experiments, 
Jurkat cells were treated with 20 µM oridonin for 2h and treated and control 
cells were exposed to varying temperature. After cooling, the samples were 
centrifuged to separate soluble fractions from precipitated proteins. We then 
quantified the presence of nucleolin in the soluble fractions by western 
blotting (Figure 19). 
 
 
Fig.19: CESTA was employed to monitor oridonin cellular target engagement and to define 
the best Tagg. Therefore, treated and untreated Jurkat cells were heated and then was evaluated 




In our experiments, 55.1 ºC was the obtained temperature to appreciate 
thermal stabilization of NCL: the amount of soluble protein at this temperature 
in the oridonin-treated cells was about 2 or 3 times higher than that observed 






Fig.20: Apparent melting curves of NCL in cell. Densitometry-based quantification of western 
blot signals was graphed (NCL intensities normalized to GAPDH intensities for each data 
point). Shown are the mean of three biological replicates. 
 
In order to investigate the kinetic profile of the engagement of NCL in cell, 
Jurkat cells were treated with oridonin (20µM) up to 4h of incubation time and 












Fig.21: Kinetic profile of the engagement of nucleolin by oridonin in cells using CETSA. 
Jurkat cells were treated with oridonin 20 µM for 1h up to 4h. Each samples was heated and 
then the soluble amount of NCL was evaluated by western blotting analysis 
 
As reported in Figure 21, the time-course experiment revealed that the 
maximum binding was observed after 2 h of incubation with oridonin; aftert 
that the difference between treated and control samples start decreasing, and it 
became negligible after 4 h of incubation . It has to be underlined that this 
result is in agreement with that achieved using the fluorescence microscopy 
(see 3.4), suggesting that oridonin uptake into the Jurkat cells and oridonin 
interaction with NCL into the same cells have a comparable kinetics. 
Taking advantage of defined Tagg, we carried out an ITDFCETSA experiment to 
establish the half-maximal effective dose (EC50) of oridonin towards NCL. 
Therefore, Jurkat cells were treated with a wide range of concentrations of 





Fig.22: CESTA in Jurkat cells in presence of DMSO or various oridonin concentration (from 
0 to 20µM) at 55.1ºC and 37ºC, and densitometry-based quantification of western blot signals 
 
Increased NCL stabilization was observed at 55.1 ºC, but not at 37ºC in a 
oridonin dose-dependent manner. The obtained EC50 was (0.8 µM) was in 
agreement with previous obtained data. 
 
3.10 Oridonin/HSP70 interaction validation in cell system using CESTA 
Since oridonin is able to bind also HSP70, as mentioned before, we decided to 
evaluate the EC50 and the kinetic profile of this complex by CETSA approach. 
The first step was to define the Tagg of HSP 70 since this temperature is cell 
model and protein specific. Therefore, Jurkat cells were treated with oridonin 
20µM for 2h and 3h of incubation time. The same experimental protocol (see 
3.9) was followed but in this case we used a specific antibody to detect the 
soluble amount of HSP70 in our samples. 
In this case the stabilization of HSP70 by its binding with oridonin was not 
observed. The possibility to establish a CETSA melting curve for a protein 
with bound ligand is dependent on whether the binding of a ligand and induces 
a stabilization of the target protein. Large proteins, including protein 
complexes, are more likely to give weaker or no ligand-induced response in 
thermal shift assays, although the limitations of assay in this respect have not 
yet established (Jafari R. at al. 2014). Moreover, we supposed that being 
HSP70 a heat shock protein, the heating of intact cells was not enough to 
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appreciate its thermal stabilization. In fact, this protein can act to protect cells 
from thermal or oxidative stress and prevents partially denatured proteins from 
aggregating, and allows them to refold. Moreover, the melting point of 
archaeal Hsp70 (DnaK) is around 60-70°C (Popp S.L. & Reinstein J. 2009). 
Therefore, CETSA assay could not be useful to study HSP70 and similar 
proteins. 
 
3.11 In vitro imaging of nucleolin colocalization with oridoninBODIPY 
FL2 
One of the most used approaches to confirm molecular interactions inside the 
cells is the co-localization analysis performed by microscopy analysis. 
Furthermore, we carried out a fluorescence microscopy analysis aimed to 
confirm the oridonin/NCL interaction. Based on the results previously 
obtained by the chemical proteomic approach (see 3.7), we supposed that the 
α,β-unsaturated carbonyl group of the diterpene was not crucial for its 
interaction with NCL, whereas it was essential for the oridonin/HSP70 
complex formation.  
 
Thus, the first step was to synthesize the fluorescent modified version of 
oridonin conjugating the dye to oridonin from its α,β-unsaturated group. In 
particular, also in this case we used BODIPY FL as dye, for the same reasons 
mentioned before. The synthetic scheme used (Figure 23) provided the final 
molecule in two step. In particular, first we conjugated oridonin to a specific 
linker via Michael addition and then to the selected BODIPY. All steps were 






Fig.23: Synthetic scheme to obtain the fluorescence modified version of oridonin BODIPY 
FL2 
 
Successively, Jurkat cells were treated with the new CID of oridonin at 20µM 
for 2h. Cells were then fixed and stained with nucleolin antibody and 
microscopy analysis were performed. 
Fig.24: Fluorescence analysis to detect oridonin (green) and nucleolin (red). Nuclei were 
stained with DAPI. The merged image shows overlapping localization of oridonin with the 
protein 
 
As depicted in Figure 24, following 2h of incubation of the Jurkat cells with 
the fluorescent oridonin a significant co localization of oridonin with nucleolin 
within cells was observed, as demonstrated by the presence of several yellow 
spots in the “merge” panel. Interestingly, this co-localization seemed to occur 




3.12 Oridonin biological effect on nucleolin into the cell 
The evidence that NCL binds oridonin opened the way to further investigation 
on the role of oridonin in the modulation of nucleolin-mediated processes, 
inside a cell system. Thus, we were intrigued by a new potential application of 
this molecule in modulating biological processes in which NCL is involved. 
On this basis, we decided to verify first, the biological relevance of the binding 
of oridonin to NCL. 
 
3.12.1 Levels and post translational modifications of nucleolin  
NCL, a ubiquitously expressed phosphoprotein constitutes almost 10% of total 
nucleolar proteins and it was first described in 1973 (Srivastava M. & Pollard 
H.B. 1999). NCL possesses three structural domains: the N-terminal domain 
contains acidic regions (rich in glutamic acid and aspartic acid) separated by 
basic stretches, the central domain contains four RNA binding domains 
(RBDs) and the C-terminal domain is rich in glycine, arginine and 
phenylalanine residues (Ginisty H et al. 1999). NCL protein has multiple sub-
cellular locations that are directly implicated in its pleotropic physiological 
functions. In the nucleolus, it is directly involved in cellular processes e.g. 
chromatin remodeling (Angelov D. et al. 2006), transcriptional regulation 
(Abdelmohsen K. & Gorospe M. 2012) ribosome biogenesis (Cong R. et al. 
2012) and telomerase activity (Lee J.H. et al. 2014). In the nucleoplasm, it 
interacts with several proteins and is involved in regulation of the cellular 
response to stress (Daniely Y. et al. 2002; Yang C. et al. 2002; Kim K. et al. 
2005; Saxena A. et al. 2006; Bhatt P. et al. 2012; Kobayashi J. et al. 2012). 
NCL constantly shuttles between the nucleus and cytoplasm where it is 
involved in many non-nucleolar functions e.g. centrosome duplication 
(Ugrinova I. et al. 2007) as well as post transcriptional and translational 
regulation of various mRNAs (Otake Y. et al. 2007; Ishimaru D. et al. 2010; 
Abdelmohsen K. et al. 2011) including p53 (Takagi M. et al. 2005). On the 
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cell surface NCL serves as are receptor, binds to several ligands to either 
mediate tumorigenesis or to relay anti-carcinogenic effects (Fujiki H. et al. 
2014). 
An altered expression and function of NCL has been correlated with many 
cancer types. Presently, there are no known mutations or splicing variants of 
NCL associated with a disease. Instead, a deregulated accumulation of the 
NCL mRNA or/and the protein is observed in different cancer cell types 
(Berger C.M. et al. 2015). It is well established that NCL promotes cell 
proliferation and survival linked to disease processes like carcinogenesis, but 
the mechanisms that control nucleolin abundance are not well understood. 
Differential NCL localization is due to changes in its isoelectric point and/or 
post-translational modifications. There is evidence that the multiple activities 
of NCL may be regulated by covalent modifications, most notably 
phosphorylation (Caizergues-Ferrer M. et al. 1989; Peter M. et al. 1990; 
Schneider H.R. et al. 1986), proteolysis (Bouche G. et al. 1984; Bourbon H.M. 
et al. 1983), autodegradation Chen C.M. et al. 1991; Fang S.H. & Yeh N.H. 
1993), and ADP-ribosylation (Leitinger N. & Wesierska-Gadek J. 1993). For 
example, the aminoterminal domain contains sites for modification by 
phosphorylation and proteolysis, whereas the carboxyl- terminal domain has 
sites for methylation and proteolysis. All of these modifications are important 
for the regulation of NCL functions.  
Therefore, as a first step in the study of the effects of oridonin treatment on 
NCL, we evaluated the levels of this protein and its fragmentation within the 
cells following their incubation with oridonin. Jurkat cells were then treated 
with oridonin for 1h up to 4h and then underwent protein extraction procedure. 
Resulting lysates were resolved by SDS PAGE and the levels of NCL were 
evaluated using nucleolin antibody. In our experimental conditions, as 
reported in Figure 25, the levels and the specific pattern of nucleolin remained 
substantially comparable to control suggesting that oridonin doesn’t change 
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cellular NCL levels. Moreover, also the fragmentation pattern of the protein 
was not affected by the treatment. Similar results were obtained when 






Fig.25: Treatment of Jurkat cells with oridonin and nervosanin B (20µM) up to 4h and 
evaluation of proteolytic fragments of nucleolin in cell 
 
A similar experiment was performed to monitor the NCL phosphorylation 
following the oridonin treatment. NCL is highly phosphorylated and its 
phosphorylation is strictly regulated during the cell cycle (Peter M. et al. 1990; 
Morimoto H. et al. 2005). Extensive phosphorylation by casein kinase 2 
(CK2) occurs at interphase and by CDC2 during mitosis and this regulated 
phosphorylation of nucleolin probably regulates nucleolin functions during the 
cell cycle (Ginisty H. et al. 1999; Peter M. et al. 1990). In addition, massive 
phosphorylation by CDC2 or CK2 kinases localizes nucleolin to the 
cytoplasm, and nuclear translocation of NCL accompanies dephosphorylation 
(Schwab M.S. & Dreyer C. 1997). Moreover, phosphorylation of nucleolin by 
CKII and CDC2 kinase has been shown to regulate its helicase activity (Tuteja 
N. et al. 1995), and phosphorylation by CK2, CDC2 kinase, PKC-j, cyclic 
AMP-dependent protein kinase, and ecto-protein kinase may regulate 
nucleolin’s functional abilities in chromatin organization, rRNA packaging, 
rDNA transcription, or ribosome assembly. 
85 
 
Hence, Jurkat cells were incubated with oridonin and evaluated the 
phosphorylation of this protein for several time points. After the last 
experimental point, 24h, oridonin treated and control (DMSO) cells were lysed 
and samples were analyzed by western blotting using phosponucleolin 
antibody. 
 
Fig.26: Effect of oridonin on phosphorylation of nucleolin in cells and densitometry-based 
quantification of western blot signals. Jurkat cells were treated with oridonin 20µM at 
indicated incubation times and followed by western blotting analysis using the phosphorylated 
NCL antibody 
 
The immunoblot profile (Figure 26) demonstrated a relevant degree of 
phosphorylation only after 12h in the cells treated with oridonin. A major 
effect was evident in the case of 24 h. This result suggests that oridonin 
induced, directly or indirectly, a late phosphorylation of this protein. 
Moreover, in order to get more information about this post translational 
modification, we performed CETSA experiments. In this case we used the 
phsponucleolin as antibody to better understand if oridonin was able to bind 
the phosphorylated nucleolin within cell. Therefore, Jurkat cells were treated 
with oridonin 20µM up to 12h and then we evaluated the engagement profile 










Fig.27: Kinetic profile of the engagement of phosphonucleolin by oridonin in cells by 
CETSA. Jurkat cells were treated with oridonin 20 µM for 30min up to 12h. Each samples 
was heated and then the soluble amount of phosphoNCL was evaluated by western blotting 
analysis 
 
The profile revealed that oridonin was no able to bind the phosphorylated 
nucleolin. Therefore, all these results indicate that oridonin binds NCL and it 
did not induce any post translational modification investigated, at least for the 
first 4 hours of incubation time. 
 
3.12.2 Regulation and influence of target mRNAs of nucleolin by oridonin 
NCL is highly expressed in proliferating cells, including stem cells and cancer 
cells. The oncogenic effect this appears to be multifactorial, in keeping with 
the many functions of this protein. Cells acquire a number of features in order 
to become malignant, including the abilities to grow and proliferate, overcome 
senescence, evade apoptosis and the immune system, invade and metastasize 
other tissues and promote angiogenesis (Hanahan D. & Weinberg R.A. 2011; 
Dunn G.P. et al. 2004). NCL through its RNA binding activity conferred by its 
four RNA binding domains could affect these traits. Toward implementing an 
anti-apoptotic phenotype, NCL modulates the expression of several proteins 
that influence the survival of malignant cells during cell damage. In fact, NCL 
affects mRNA turnover, both increasing and decreasing mRNA half-life, by 
interacting with the 3'-untranslated region of several target mRNAs. In 
particular, NCL binds to BCL2 mRNA and promotes the expression of proto-
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oncogene Bcl-2 which blocks apoptosis in cancer cells (Yang J. et al. 1997), 
and it binds to AKT1 mRNA and enhances translation of Akt1, another potent 
pro-survival protein (Hers I. et al. 2011). On this basis, we decided to verify 
oridonin effects on the levels of these specific mRNAs. Hence, Jurkat cells 
were treated with 20 µM oridonin for 3h and 6h and the stabilization of Bcl2 
and AKt1 mRNAs by Real-Time Quantitative Polymerase Chain Reaction 
(rtq-PCR) was evaluated. As reported in Figure 28 the levels of these mRNAs 
decrease in a time-dependent manner. 
Fig.28: rtq-PCR of AKT1 and BCL2 mRNAs and western blot analysis of these proteins. 
Jurkat cells were treated with oridonin 20µM for 3 and h and either AKT1 and BCL2 mRNAs 
and levels of these proteins were analyzed 
 
Moreover, all of these results were confirmed by western blotting analysis as 
reported in the same Figure 28. In fact, we estimated also the amount of these 
two proteins by western blotting. 
 
3.12.3 Inhibition of protein synthesis by oridonin 
Ribosome biogenesis involves rRNA synthesis, maturation, and assembly of 
rRNA and ribosomal proteins into the large and small ribosome subunits. This 
process is regulated throughout the cell cycle, primarily at the level of rRNA 
synthesis (Hannan K.M. et al. 1998). rDNA transcription peaks during the S 
and G2 phases, stops as cells enter mitosis and then reactivates as cells exit 
from mitosis. Many factors have been shown to participate in various steps of 
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the processing. These extensive modifications generate 18S, 5.8S, and 28S 
rRNA. The mature rRNAs are subsequently assembled with ribosomal 
proteins into preribosomal particles in the nucleolus (Grummt I. 1999). 
NCL plays important roles in various steps of ribosomal synthesis, such as the 
transcription of rDNA repeats, the modification and processing of pre-rRNA, 
the assembly of pre-ribosomal particles and nuclear-cytoplasmic transport of 
ribosomal proteins and subunits. In particular, nucleolin involvement in rDNA 
transcription, pre-RNA processing, ribosome assembly, and maturation 
mediated through the interaction of nucleolin with rDNA (nontranscribed 
spacer, 59 and 39-external nontranscribed spacer, internal transcribed spacer, 
nascent 45S pre-RNAs, RNA polymerase 1, 18S, 28S rRNAs) and ribosomal 
proteins could be an efficient way for the cell to regulate the production of 
large amount of ribosomes needed throughout its life (Ginisty H. et al. 1999; 
Tuteja R. & Tuteja N. 1998;, Srivastava M. & Pollard H.B. 1999). 
Ribosomes are the sites in a cell in which protein synthesis takes place and this 
process is crucial to cell growth, proliferation, and adaptation to changing 
environment. Since the main role of NCL about ribosome biogenesis, the 
effects of oridonin treatment on protein synthesis in different experimental 
conditions were investigated. Therefore, in a first step of the protein synthesis 
assay, different samples of Jurkat cells were analyzed: cells incubated with 
oridonin 20µM for 1h, cells with oridonin 20µM for 2h, cells with nervosanin 
B 20µM for 2h, with cycloheximide (a well-known inhibitor of the protein 
synthesis) and with DMSO (as negative control). After the incubation, the 
samples were treated with Click-iT
®
 OPP (O-Propargyl-Puromycin). This 
reagent is a puromycin analog containing an alkyne moiety. When added to 
culture media, OPP is readily taken up by actively growing cells. OPP inhibits 
protein synthesis by disrupting peptide transfer on ribosomes causing 
premature chain termination during translation. Addition of the 5 FAM azide 
and the click reaction reagents led to a chemoselective ligation or “click” 
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reaction between the azide dye and the alkyne OPP, allowing the modified 
proteins to be detected. Finally, all the samples were analyzed by flow 
cytometry. 
As depicted in Figure 29, the shift in the maximum fluorescence intensity is 
clearly due to the OPP alone without any inhibitor. Lower fluorescence 
intensity gave cycloheximide, as expected, since it’s able to block this process. 
Oridonin gave a decreasing of the signal in time-dependent manner, and after 
2h gave the same % of inhibition as cycloheximide suggesting a strong 
inhibition of the protein synthesis process. Nervosanin B gave no inhibition of 











Fig.29: FACS analysis of Jurkat cells to evaluate the inhibition of the protein synthesis: Blue 
signal: Jurkat cells were treated with nervosanin B 20µM for 2h; Red signal: Jurkat cells were 
treated with OPP; Green signal: Jurkat cells were treated with oridonin 20µM for 1h; Purple 
signal: Jurkat cells were treated with oridonin 20µM for 2h; Black signal: Jurkat cells were 
treated with cycloheximide 
 
All these data clearly demonstrated the ability of oridonin to inhibit the protein 
synthesis process in a time-dependent manner. 
Since is reported that oridonin is able to arrest cell cycle in S-G2/M phase (Dal 
Piaz F. et al. 2013), we verified if in our experimental condition there was 
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already the block of the cell cycle and consequently the inhibition of the 
protein synthesis. With this purpose, Jurkat cells were treated with oridonin 
20µM, nervosanin B 20µM, and vehicle for 2h and stained with propidium 
iodide. Samples were then analyzed by FACS to evaluate cell viability and 






Fig.30: Cell cycle analysis of Jurkat cells after treatment with oridonin and nervosanin B 20 
µM for 2h 
 
Indeed, as reported in Figure 30, oridonin did not produce significant cytotoxic 
effects on Jurkat cells and changes in cell cycle vs control even at 20 µM for a 
short incubation time (2h). These results confirmed the influence of oridonin 
on protein synthesis and its ability to bind NCL and to affect its biological 
activity in cell. 
 
3.13 Screening in vitro of new potential nucleolin inhibitors using CETSA 
approach 
The results obtained on oridonin strongly suggests this diterpene as an 
effective modulator of NCL. Presently, in literature there are two reported 
inhibitors of NCL: the first is AS1411 that is a 26-base G-rich DNA 
oligonucleotide that functions as a nucleolin-binding aptamer and has 
antiproliferative activity against a wide range of cancer cells, but little or no 
effect on nonmalignant cells (Wu D.M. et al. 2014). The second is HB 19, a 
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synthetic multimeric pseudopeptide, that binds cell surface expressed 
nucleolin and inhibits both tumor growth and angiogenesis (Birmpas C. et al. 
2009). Therefore, considering the new interest and potential of NCL as 
druggble protein, could be very advantageous to discover new small molecule 
as potential inhibitors. Thus, we attempted to identify new compounds able to 
bind nucleolin in cell, starting from oridonin analogous. Therefore, we 
developed a highly sensitive CETSA approach for the screening of natural 
compounds. This target-based technique is very useful since can give critical 
target engagement informations for a range of different drugs target directly in 
cell. In particular, this approach can address the fundamental question of 
whether the drug candidates actually engage their intended targets in a 
biological relevant settings and at what concentration regimes they exert their 
effects and it could serve to identify starting points for medicinal chemistry 
programs. As many target classes offer a broad range of screen assay 
alternatives, this approach may be of particular interest for targets that are 
difficult to express and purify in a biologically active and relevant form or for 
which other assay formats are difficult to establish for technical reasons. 
Moreover, CETSA approach, rarely gives false positive ligand-binding data, in 
contrast to many activity-based assay (Jafari R. et al. 2014).  
Our program started with a screening of ent-kaurane diterpenes, using oridonin 
as positive control. Experimental conditions were set as reported for oridonin 
(see 3.9). A small number of diterpenes were selected on the basis of their 
structural homology to oridonin, from the wide collection of natural 
compounds isolated and fully characterized by our research group (Figure 31). 
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Fig.31: Chemical structure of tested molecule by CETSA 
 
Experimentally, Jurkat cells were treated with selected compounds at 20 µM 
for 2h of incubation time (Figure 32). Next, we heated samples at the defined 
Tagg for nucleolin in this cell model and we kept constant all parameters for 
each samples. Finally, we used nucleolin antibody to detect the soluble amount 
of this protein in our samples. The achieved results were used to establish new 












Fig.32: CETSA approach to establish new potential tools for the interaction with nucleolin. 
Jurkat cells were treated with DMSO or with a small molecule at 20µM for 2h of incubation 
time, followed by heating of each samples at 55.1ºC. Western blotting using NCL antibody 
was performed 
 
Only ponidonin, a compound having close similitude to oridonin both under 
structural and biological point of view, showed an affinity towards NCL 
comparable to that of oridonin. Moreover, looking the investigated structures 
and obtained results suggested that α,β-unsaturated carbonyl group of oridonin 
structure it did not play a crucial role for the interaction with NCL. Finally, 




In the present research, the mechanism of action of oridonin was investigated 
by adopting a multidisciplinary approach. Oridonin, the main bioactive 
diterpenoid isolated from the well known plant Isodon rubescens, has been 
shown to have multiple biological activities. Among them, the anticancer 
activities have been repeatedly reported by many research groups (Sun H.D. et 
al. 2006; Sartippour M.R. et al. 2005; Tan W. et al. 2011; Li C.Y. et al. 2011). 
The chemopreventive and antitumor effects of oridonin have been related to its 
ability to interfere with several pathways involved in cell proliferation, cell 
cycle arrest, apoptosis and/or autophagy (Zhang T.M. 1982). 
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This diterpene had already aroused interest in our research group. Using an 
unbiased chemical proteomic approach we defined the possible protein target 
of the ent-kaurane diterpene oridonin. In particular, HSP 70 was find out as 
main target of this molecule. Although many of the activities of this protein 
could explain the mechanism of action of this molecule, the complex 
mechanism of action of oridonin was not entirely clear. Moreover, the 
technique used for the identification of the target is one of the most effective 
to define the interactome of a bioactive compound, but it faces some 
limitations (Rix U. & Superti-Furga G. 2009). 
Therefore, with the aim to expand our knowledge about this molecule, we 
carried out a study based on the use of several techniques complementary and 
orthogonal each other. The first step was to synthesize the fluorescence 
modified oridonin version to better understand the uptake and the kinetic 
profile of this molecule in our cell model. Once we established the complete 
kinetic profile of this molecule for the first 4h of treatment, we carried out an 
indirect unbiased proteomic study to define protein targets of our diterpene. 
We used DARTS approach which allowed us first to validate the interaction 
with HSP70 but also to define a new list of interactors within cells. The study 
of small molecules/protein interactions using DARTS approach has the 
advantages of use the molecule without chemical modifications. Thereafter, 
we conducted a chemical proteomic study. In particular, the aim has been to 
enhance and then evaluate possible noncovalent interactors of oridonin. In 
fact, although oridonin has the α,β-unsaturated carbonyl group in the structure 
as pharmacophore, in order to make a very stable interaction with a target it’s 
important also the interactions of the carbon skeleton of the same molecule 
with it. Also this study allowed us to define a possible list of putative target of 
oridonin within cell. 
Crossing all the obtained results we focused our studies on nucleolin. This is a 
ubiquitousphosphoprotein and a multifunctional phosphprotein, over 
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expressedin cancer cells (Derenzini M. et al. 1995; Srivastava M.& Pollard 
H.B. 1999) where it can influence cancer development. We confirmed the 
ability of oridonin to interact with NCL and evaluated the effects of this 
interaction on NCL activity. Firstly, we defined the thermodynamic 
parameters of the NCL/oridonin complex formation in vitro using SPR 
analysis, demonstrating that oridonin has a high affinity towards this protein. 
Subsequently, we evaluated if the treatment of the cells with oridonin can 
affect the levels and the post translational modifications of this protein. Our 
data indicate that oridonin does not affect some of these parameters and, above 
all it selectively binds the unmodified full length protein. Finally, in order to 
understand the consequences of the NCL-oridonin interaction on protein 
activity, we deeply investigate how oridonin influence several specific 
pathways in which NCL plays a fundamental role. Therefore, specific mRNAs 
stability and protein synthesis were evaluated. Last step was to support all the 
data obtained before. Therefore, by microscopy analysis it was possible to 
prove, once again, the possible interaction within cell between oridonin and 
nucleolin. 
The identification of HSP70 and nucleolin as oridonin molecular targets in 
Jurkat cells suggested a mechanism of action of oridonin consistent with the 
multiple biological activities described for this diterpene. Specifically, 
achieved results suggest that although oridonin is able to bind different 
partners inside the cell, it mainly affects a specific pathway. Several evidences 
have been reported indicating that HSP70 promote cell protection from 
external injuries also by enhancing the stability and the activity of NCL (Xu J. 
et al. 2010); the contemporaneous inhibition of HSP70 and NCL could 
therefore produce significant effects on cell viability and proliferation (Xu Z. 
et al. 2012). Moreover, HSP70 activity is needed to allow the translocation of 
NCL to the cancer cell membranes, where it plays a pivotal role in the 
angiogenic induction (Ding Y. et al. 2012); thus oridonin could strongly affect 
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neovascularization of cancer tissues. These findings, shedding light on the 
molecular basis of the biological activity of oridonin, may therefore be 
extremely relevant for possible therapeutic applications of oridonin, opening 
the way to the design of new therapeutic approaches. Some compounds 
inhibiting HSP70 underwent preclinical and clinical studies exploring the 
effect of a combination of HSP inhibitors with other anticancer agents in 
cancer therapy, demonstrating that in most cases they produce additive or 
synergic effects (Mosser D.D. & Morimoto R.I. 2004; Brodsky J.L. & Chiosis 
G. 2006; Yerlikaya A. et al. 2010). In addition, several molecules have been 
developed to block the action of NCL, but only the aptamer AS1411 is still 
continuing its stages as NCL-inhibitory molecule in clinical trials. However, 
oridonin could be the first example of a small molecule affecting the activities 
of both these proteins. Thus, this diterpene could be the ideal starting point to 
design optimized multi-target inhibitors, but it also represents a useful tool to 
better understand the structural and functional features of HSP70 and NCL. In 
addition, this research demonstrates the effectiveness of a multidisciplinary 




Materials and methods 
 
3.15 Synthesis and Characterization of Oridonin-BODIPY FL 
 
Materials 
All reagents were obtained from commercial sources and used without further 
purification. Dry THF, DCM, and DMF were obtained from Sigma Aldrich 




C NMR spectra were recorded at 23 ⁰C on Burker 400MHz 
spectrometer. LC-ESI-MS analysis and HPLC purifications were performed 
on a Waters (Milford, MA, USA) LC-MS system. 
 
 
3.15.1 Synthesis and charactherization of ent-1a,6b-Dihydroxy-7,14-
isopropylidene ketal-15-oxo-7,20-epoxy-16-kaurene (compound 1) 
Briefly as reported by Wang L. et al. 2012: Oridonin (100 mg, 0.27 mmol) 
was dissolved in acetone (10 ml). TsOH (5 mg) and 2,2-dimethoxypropane (1 
ml) were added to this solution. The mixture was stirred at R.T. for 15 min, 
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and diluted with water and extracted with dichloromethane for 3 times. The 
extract was washed with saturated NaHCO3 solution and brine, dried over 
anhydrous Na2SO4, filtered, and evaporated to afford compound 1 (94 mg, 
85%) as a white powder. LRMS (ESI) m/z calcd for C23H32O6= 404.22 
 
3.15.2 Synthesis of compound 2 
Compound 1 (32mg mmol0.0792) was dissolved in dry DCM (700µl). This 
solution was purged with nitrogen for 10 min. DMAP (38.7 mg 0.316mmol) 
and 4Nitrophenyl Chloroformate (32 mg 0.158mmol) were added. The 
mixture was stirred at R.T. for 1h. After reaction completion, the mixture was 
dried and then purified with silica gel column chromatography (Ethyl Acetate : 
Hexane 0:100 to Ethyl Acetate only) to give compound 2 (13 mg, 40%) as a 
white powder. LRMS (ESI) m/z calcd for C30H35NO10 =569.23 
 
3.15.3 Synthesis of compound 3 
A solution of compound 2 (10mg 0.024mmol), DIPEA (7ul 0.05 mmol) was 
addes. After 5 min, BODIPY ammine (26mg 0.05mmol) in DCM: DMF 50:50 
(900µl) was added. The mixture was stirred at R.T. for 1h. After reaction 
completion, the mixture was dried and then purified with a C18 reverse phase 
column (Water : ACN w/0.1% Formic acid = 95:5 to 0: 100) to give 
compound 3 (14mg, 81%). LRMS (ESI) m/z calcd for C39H50BF2N3O7=721.37 
 
3.15.4 Synthesis of compound 4 
In order to get the final compound, compound 3 (10mg 0.014 mmol) was 
dissolved in THF: HCl 10% (2ml) and stirred the solution at R..T. After 1h the 
mixture was dried and then purified with a C18 reverse phase column (Water : 
ACN w/0.1% Formic acid = 95:5 to 0: 100) to give compound 4 (6.8mg, 




3.15.5 Stability assay 
In order to get information about stability of oridonin BODIPY FL in our 
experimental conditions, 300µg of this compound was dissolved in different 
buffers (1ml each): PBS, Sodium Carbonate Bicarbonate 0.5 M pH=10 buffer, 
0.1M MES buffer pH=5 and complete growth buffer (RPMI 1640 medium 
supplemented with 10% (v⁄v) FBS). After different time points (from T0 to 
T24h), 100µl of each solution was analyzed by LC-MS. 
 
3.16 Biological characterization of oridonin BODIPY FL 
 
Materials 
Fetal Bovine Serum (FBS) was from GIBCO (Life Technologies, Grand 
Island, NY, USA) and all the other reagents were from Sigma-Aldrich (St. 
Louis, MO, USA). 
 
3.16.1 Cell Viability Assay 
Jurkat cells, obtained from American Type Culture Collection (ATCC) 
(Manassas, VA, USA), were maintained in RPMI 1640 medium supplemented 
with 10% (v⁄v) FBS, 2 mM L-glutamine and antibiotics at 37 ºC in humidified 
atmosphere with 5% CO2. To ensure logarithmic growth, cells were sub-
cultured every 2 days. Under given experimental conditions, untreated Jurkat 
cells were able to double in number in 24 h. All experiments were performed 
using cells seeded at 2x10
5
 cells/ml. 
The number of viable cells was quantified by MTT ([3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide]) assay. Absorption at 550 nm was 
assessed using a microplate reader (LabSystems, Vienna, VA, USA). In some 
experiments cell viability was also checked by Trypan Blue exclusion assay 
using a Bürker counting chamber. 
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More in details, cells were seeded in 96-well microtiter plates in 100 µl of 
growth medium. After 24 h and 48h of incubation at 37 °C, cells were exposed 
to different concentration of oridonin and oridonin BODIPY FL, ranging from 
0.01 μM to 40 μM, containing as final concentration of DMSO 0.1%. The 
same amount the of DMSO has been applied as control and the incubation was 
carried out for the same incubation times. The mitochondrial-dependent 
reduction of MTT to formazan was used to assess the possible cytotoxic effect 
of these compounds. The experiment was carried out in triplicate and all the 
values were normalized to control. 
 
3.16.2 Covalent binding Oridonin BODIPY FL/ HSP70 
The ability of oridonin BODIPY FL to stabilize HSP70 with covalent binding 
mode was investigated. Dal Piaz F. et al. 2013 provided the high stability and 
the covalent binding of oridonin/HSP70 in vitro. Therefore, in order to get a 
full characterization of the modified version of oridonin was repeated the same 
experiment in the same conditions. More in details, 0.5µg (per data point) of 
human recombinant HSP70 (GenBank No. NM_005345, Tebu-Bio, Milano, 
Italy) was incubated with different fold molar excess (starting from 0.01 up to 
10 molar folds more) of oridonin BODIPY FL in PBS at 25 °C under stirring 
for 15 min. Each sample was loaded on a mono-dimensional 12% SDS-PAGE 
and stained with Brilliant Blue G-Colloidal. Moreover, using Typhoon scanner 
FLA 7000 (GE Healthcare Life Sciences) was possible to detect the 
fluorescence intensity of oridonin BODIPY FL into the gel (ex: AlexaFluor 
488nm, em: 512nm) 
 
3.17 Live cell fluorescence microscopy in cell of oridonin BODIPY FL 
Jurkat cells were seeded into a 96-well plate at 5000 cells per well and 
incubated for 24h. Cells were incubated in growth media containing 5 µM of 
oridonin BODIPY FL 0.1% DMSO for 1h up to 4h. When the incubation time 
101 
 
was done, Hoechst 33342 (ThermoFisher scientific) was added to each sample 
for 30 min. Live cells were subsequently imaged on a Delta Vision imaging 
system (Applied Precision, GE Healthcare). Images were processed using Fiji 
software, an open-source version of ImageJ. 
Next experiment was to repeat the same kind of analysis mentioned before but 
the cells were washed before the microscope analysis. Jurkat cells were treated 
with oridonin BODIPY FL for 2h and then replaced with growth medium 
supplemented with FBS 10% (v/v) for 1h, 2h and 3h. Live cells were then 
imaged.  
 
3.18 Target identification approaches 
 
Materials 
Bredford and Brilliant Blue G-Colloidal were from BioRad, 1,4 Dithiothreitol 
and iodoacetamide were from AppliChem. All the other reagents were from 
Sigma-Aldrich (St. Louis, MO, USA). 
Antibodies: anti-HSP-70 (mouse monoclonal, sc-32239), anti-Trx (rabbit  
polyclonal sc-20146), anti-GAPDH (rabbit polyclonal, sc-25778) and anti-
HSP-90α/β (rabbit  polyclonal, sc-7947),  were obtained from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA); antti-TRXR1 (rabbit polyclonal, 6925) 
from Cell Signaling Technology (Danvers, MA, USA); anti-PPARγ (mouse 
monoclonal, ab-45036) and anti-nucleolin (rabbit polyclonal, ab22758) were 
from Abcam (Cambridge, CB4 0FL, UK). Peroxidase-conjugated secondary 
antibodies were from Jackson ImmunoResearch (Baltimore, PA, USA). 
 
3.18.1 Optimization of DARTS protocol 
Jurkat lysates (50 µg) were incubated with DMSO (1% v/v as final 
concentration) and after 1h of incubation time subtilisin digestion was 
followed. Different ratio enzyme: lysate (starting from a range of 1:100 up to 
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1:2500 w/w) for 30 min at R.T. under stirring was added to each samples. 
Each sample was then boiled for 5min at 100 ⁰C with Laemmli buffer 1X. 
Finally, proteins were loaded on a mono-dimensional 10% SDS-PAGE and 
stained with Brilliant Blue G-Colloidal. 
 
3.18.2 Evaluation of oridonin interference with subtilisin using DARTS 
approach 
Recombinant BSA protein (10 µg) was incubated with and without oridonin 
(20 µM 1%DMSO) in PBS for 1h at R. T. under stirring. Proteolysis of each 
sample 1:1000 (w:w) subtilisin : BSA for 30 min was followed. Moreover, the 
same amount of subtilisin was incubated with oridonin 20 µM 1% DMSO for 
1h. Peptides were then resolved by mono dimensional 10% SDS-PAGE gel 
and stained with Brilliant Blue G-Colloidal. Subtilisin digestion of BSA as a 
nonbinder protein of oridonin was unaffected by oridonin. 
 
3.18.3 DARTS experiment on whole cell lysate 
Human Jurkat cells were lysed in RIPA buffer supplemented with protease and 
phosphatase inhibitors. Protein concentration was determined by Bredford 
assay using bovine albumin as a standard. Lysates (50 μg) were incubated with 
2 μl of PBS 8.5% DMSO, or 2μl of oridonin 170μM 8.5% DMSO in PBS, or 2 
μl of Nervosanin B 170μM 8.5% DMSO in PBS to obtain the final 
concentration of 20 μM 1% DMSO for each small molecule studied. The 
samples were incubated for 1h at R.T. under stirring. Samples were then 
underwent proteolysis with Subtilisin (enzyme: lysate 1:1000 w/w) for 30 min 
and then, 5 μl of Laemmli buffer 4X was added to each sample and incubated 





3.18.4 DARTS experiment on intact cell 
Intact Jurkat cells (2 million of cells per data point) were treated with oridonin 
to obtain the final concentration of 10 μM and 20 μM or 0.1% DMSO control 
for 2h at 37 °C. Cells were then lysed with RIPA buffer supplemented with 
protease and phosphatase inhibitors. After centrifugation and determination of 
protein concentration, the lysates were diluted to the same final volume with 
PBS. Each sample (50 μg) was then quickly warmed to room temperature and 
proteolysed with subtilisin (enzyme: lysate 1:1000 w/w) for 30 min at R.T. 
Therefore, 5μl of Laemmly buffer 4X was added to each sample and incubated 
at 100°C for 5 min. Mixtures were resolved by 10% mono dimensional SDS-
PAGE gel. 
 
3.18.5 “Complementary” chemical proteomic 
To perform a proteomic analysis of potential oridonin target protein(s), the 
first step was to modified the resin with oridonin. Specifically, about 300 μg 
Resin TentaGel HL-S-Trityl (FLUKA-Sigma Aldrich) was washed with 100 
μl of MeOH/TFA/TIS (94:1:5 v:v:v) for three times. Subsequently, was added 
100 μl of 5% TFA in MeOH for 20 min at r.t. The activated resin was 
incubated with 4μg Oridonin (equimolar amount 12nmol 1:1 ratio resin : 
oridonin) and the mixture was maintained under continuous shaking O.N. at 
R.T.  
The amount of immobilized oridonin was calculated integrating the peaks of 
the free oridonin species after HPLC injections of supernatants at t = 0 h, t= 2h 
and t=O.N., using an Agilent 1200 Series chromatographer. The HPLC runs 
were carried out onto a Phenomenex C18 column (250 x 2.0 mm) at a flow 
rate of 200 μl/min. The gradient (Solution A: 0.1% F.A., solution B: CAN, 
0.1% F.A.) started at 20% and ended at 95% B after 25 min. The residual thiol 
groups were inactivated with β mercaptoethanol. To obtain the control matrix, 
activated resin TentaGel was mixed with β mercaptoethanol. The mixture was 
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manteined under shaking O.N. at R.T. The amount of immobilized oridonin 
was 71%. 
Jurkat cell lysates (400 μg) were incubated with resin modified with oridonin 
and without for 2h at 4°C undershaking. The beads were washed three times 
with PBS. Interacting proteins were eluted by 15 μL of Laemmli buffer 4X. 
Eluted proteins were separated on a mono-dimensional 10% SDS-PAGE and 
stained with Brilliant Blue G-Colloidal. Each gel line was cut in 10 pieces, and 
digested as describe below. 
 
3.18.6 Samples preparation for mass spectrometer analysis 
In gel digestion by trypsin was performed as previously described (Dal Piaz F. 
et al. 2013). Briefly, the lanes of interest were excised manually and analyzed 
as follow: gel pieces were discolored and de-hydratated in ACN. Subsequenty, 
samples were subjected to reduction in 10mM 1-4 dithiothreitol (DTT) for 1 
hour at 56°C and alkylated in 55mM iodoacetamide (IAA) for 30 min at r.t. in 
the dark. Samples were washed again, with ACN and Ammonium bicarbonate 
100mM and finally digested with 30µl of trypsin, from porcine pancreas 
(Sigma Aldrich) at a final concentration of 0.013 ng/µl. Supernatans were 
collected, vacuum dried, dissolved in 15µl of 5% Formic acid for MS analysis. 
The resulting fragments were extracted and analyzed by LC/MS/MS using a 
LTQ Orbitrap XL ESI-mass spectrometer (Thermo Fisher Scientific) equipped 
with a nano-ESI source, coupled with a nano-Aquity capillary UPLC (Waters): 
peptides separation was performed on a capillary BEH C18 column (0.075 
mm × 100 mm, 1.7 µm, Waters) using aqueous 0.1% formic acid (A) and 
CH3CN containing 0.1% formic acid (B) as mobile phases. Peptides were 
eluted by means of a linear gradient from 10 % to 4 0% of B in 45 min and a 
300 nl•min-1 flow rate. Peptide fragmentation was achieved using helium as 
collision gas and a collision cell energy of 30 eV. Mass spectra were acquired 
in a m/z range from 400 to 1800, and MS/MS spectra in a m/z range from 25-
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2000. MS and MS/MS data were used by Mascot (Matrix Science) to 
interrogate the Swiss Prot non-redundant protein database. Settings were as 
follows: mass accuracy window for parent ion, 10 ppm; mass accuracy 
window for fragment ions, 50 millimass units; fixed modification, 
carbamidomethylation of cysteines; variable modifications, oxidation of 
methionine. Proteins with scores > 65 and identified by at least 2 significant 
sequences, were considered as reliable proteins. 
 
3.19 SPR analysis of nucleolin complexes 
SPR studies on oridonin and on nervosanin B were performed using an optical 
biosensor BIACORE 3000 (GE Healthcare,Milano, Italy). Briefly, 
recombinant human nucleolin was immobilized on a CM4 sensor chip using a 
5 μM solution in sodium acetate 50 mM, pH 4.5. The carboxylic groups of the 
chip were previously activated by EDC 0.2 M and NHS 0.05 M. The 
exceeding active groups were inactivated with ethanolamine 1 M. To study the 
interaction of oridonin and nervosanin B with immobilized nucleolin, 
diterpenes stock solutions (4 mM) in DMSO were diluted 1:1000 in PBS to get 
a final DMSO concentration of 0.1%. Compound concentration series were 
prepared as 2-fold dilutions into PBS: for each sample, the complete binding 
study was performed using a six-point concentration series, typically spanning 
0.001 to 0.5 μM, and triplicate aliquots of each compound concentration were 
dispensed into single-use vials. Binding experiments were performed at 25 °C, 
using a flow rate of 50 μL/min, with 60 s monitoring of association and 200 s 
monitoring of dissociation, using PBS as running buffer. Simple interactions 
were adequately fit to a single-site bimolecular interaction model, yielding a 
single KD. Sensorgram elaborations were performed using the BIAevaluation 




3.20 CETSA approach 
 
Materials 
Antibodies: anti nucleolin Phosphorylated (Thr76/Thr84) (anti mouse 
polyclonal 10C7) from BioLegend (San Diego, CA, USA) 
 
3.20.1 Determination of the apparent melting curve of nucleolin by CETSA 
Protocol used was adopted from Jafari R. et al. 2014 but slightly modified. 
More in details, approximately 10 million Jurkat cells in a final volume of 
10ml of growth media were used for each condition, in a Cell Culture Flasks 
(T75). A stock solution of oridonin (10μl of 20mM in DMSO) was added to 
individual flasks to get a final concentration of 20 μM of oridonin (0.1% 
DMSO); 10μl DMSO was used as control. Cells were gently mixed by 
pipetting up and down at least 3 times and were incubated for 1h up to 4h in 
the CO2 incubator at 37 °C. After, the cell suspensions were collected and 
transferred to 15-ml conical tubes. Once cells were centrifuged, pellets of cells 
were washed with PBS and gently resuspended in 1ml of PBS supplemented 
with protease inhibitors to each respective tube. Each cell suspension was 
divided into 10 different tubes and the heated using PCR machine (Invitrogen 









The temperature used were: 
Temperature (⁰C) Sample CTR Sample Treated 
40.2 1 11 
42.6 2 12 
46.3 3 13 
48.3 4 14 
53.6 5 15 
55.1 6 16 
58.1 7 17 
60.5 8 18 
64 9 19 
66.6 10 20 
 
Immediately after heating, tubes were kept at room temperature for 3 min. 
After this 3-min samples were immediately snap-freezed in the liquid nitrogen 
for 3 times. Therefore, cell lysate–containing tubes were centrifuged at 
20,000g for 20 min at 4 °C to pellet cell debris together with precipitated and 
aggregated proteins. Each supernatant with the soluble protein fraction was 
transferred to a new tube. Subsequently 10µl of each tubes were loaded on a 
10% mono dimensional SDS-PAGE gel and western blotting analysis was 
performed. 
 
3.20.2 Determination of EC50 of complex nucleolin/oridonin by CETSA 
To perform the ITDRFCETSA experiments, equal number of Jurkat cells (1 
million cells per data points) were seeded in 24 well cell culture plates in 1 ml 
of growth media ad exposed to varying concentration of oridonin for 2h of 
incubation time in an incubator chamber (range used from 0.25 µM to 20 µM, 
final concentration of DMSO 0.1%). Following the incubation, the drug-
containing media were removed by centrifugation cells were washed with PBS 
and prepared for CETSA experiment. In this case cells were heated at 55.1 ⁰C 
for 3min and the protocol used was the same described before. All 
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immunoblots were processed using Fiji software, an open source version of 
ImageJ. 
 
3.21 Biological effect of oridonin in cell 
 
Materials 
Trizol Reagent, RNAse H, SuperScript® II Reverse Transcriptase, random 
primers, and dNTP mix were purchased from Invitrogen (Life Technologies, 
Grand Island, NY, USA). SYBR Green I Master Mix and DNase I were from 
Roche Applied Science (Mannheim, Germany). Primers (custom synthesized) 
were from Primmbiotech (Milano, Italy) and all the other reagents were from 
Sigma-Aldrich (St. Louis, MO, USA).  
Antibodies: Anti -tubulin (mouse monoclonal, sc-32293), anti-Bcl-2 (C-2, 
mouse monoclonal, sc-7382), were obtained from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA); anti-Akt (rabbit polyclonal, 9272) from Cell 
Signaling Technology (Danvers, MA, USA). Peroxidase-conjugated secondary 
antibodies were from Jackson ImmunoResearch (Baltimore, PA, USA). 
 
3.21.1 RNA isolation and quantitative real-time RT-PCR (qRT-PCR) 
Jurkat cells were treated with oridonin 20 µM 0.1% DMSO as final 
concentration for 3h and 6h. 
Total RNA was isolated using Trizol Reagent according to the manufacturer’s 
instructions and spectrophotometrically quantified. RNA integrity was 
assessed by agarose gel electrophoresis. RNA (3 µg) was reverse transcribed, 
and real-time PCR was performed with Light-Cycler® 480 (Roche 
Diagnostics GmbH, Mannheim, Germany) using SYBR Green detection in a 
total volume of 20 µl with 1 µl of forward and reverse primers (10 mM) and 
10 µl of SYBR Green I Master Mix. Reactions included an initial cycle at 95 
°C for 10 min, followed by 40 cycles of denaturation at 95 °C for 10 sec, 
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annealing at 56°C for 5 sec, extension at 72 °C for 15 sec. The 18S RNA was 
used as an internal standard. The following primer sets were used for real-time 
PCR to assay specific mRNAs:  
 
forward AKT 5’-TCT ACA CCC ACA GAT GAC AG-3’ 
reverse AKT 5’-CTC AAA TGC ACC CGA GAA AT-3’ 
forward bcl-2 5’-GGA AGT GAA CAT TTC GGT GAC-3’ 
reverse bcl-2 5’-CTC CAT CAG CTT CCA GAC AT-3’ 
forward 18S 5’-CGA TGC TCT TAG CTG AGT GT-3’ 
reverse 18S 5’-GGT CCA AGA ATT TCA CCT CT-3’  
 
3.21.2 Protein Synthesis assay 
Jurkat cells were incubated with 20 µM oridonin at different time with 
nervosanin B 20µM for 2h or with 50 μg/ml cycloheximide (CHX), as positive 
control, for 30 minutes in a cell culture incubator. Cells were then processed 
for detection of protein synthesis according to the protocol described in the 
Protein Synthesis Assay Kit (Cayman Chemical, Michigan, USA). 
 
3.21.3 Cell viability and cell cycle analysis 
Jurkat cells were treated with oridonin and nervosanin B at final concentration 
of 20 µM 0.1% DMSO. Cell cycle was evaluated by propidium iodide (PI) 
staining of permeabilized cells according to the available protocol and flow 
cytometry (BD FACSCalibur flow cytometer, Becton Dickinson, San Jose, 
CA, USA). Data from 5000 events per sample were collected. The percentages 
of the elements in G0/G1, S and G2/M phases of the cell cycle were determined 





3.22 Synthesis and characterization of oridonin BODIPY FL2 
 
Materials 
All reagents were obtained from commercial sources and used without further 
purification. Dry DMF and all other reagents were obtained from Sigma 




C NMR spectra were recorded at 23 ⁰C on Burker 400MHz 
spectrometer. LC-ESI-MS analysis and HPLC purifications were performed 
on a Waters (Milford, MA, USA) LC-MS system. 
 
3.22.1 Synthesis and charactherization of compound 1 
Oridonin (100 mg, 0.27 mmol) was dissolved in MeOH (1 ml). β-mercapto-
ethyl-amine (42 mg, 0.54 mmol) in 1ml of MeOH and triethylamine (1% v/v) 
were added to this solution. The mixture was stirred at R.T. After 30 the 
mixture was dried and then purified with a C18 reverse phase column (Water : 
ACN w/0.1% Formic acid = 95:5 to 0: 100) to give compound 1 (102 mg, 
90%) as a white powder. LRMS (ESI) m/z calcd for C22H35NO6S= 441.22 
 
3.22.2 Synthesis and charactherization of compound 2 
1 mg of oridonin-mercapto-ethyl-amine (compound 1) has been conjugated 
with 1.7 mg of BODIPY FL in 1 mL of DMF:PBS buffer (80:20 v/v) for 2h at 
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37°C under stirring. Compound 2 (1.3 mg, 85%) has been monitored by RP-
HPLC-UV. LRMS (ESI) m/z calcd for C36H48BF2N3O7S=715.66 
 
3.22.3 Immunofluorescence and co localization of oridonin BODIPY FL2 
Control and oridonin-treated Jurkat cells (5µM oridonin- BODIPY FL2 for 2h) 
were fixed in a freshly prepared mixture of 4% paraformaldehyde in PBS for 
30 minutes and permeabilized with 0.1% Triton X100 for 10 minutes. After 
washing with PBS, cells were incubated with primary rabbit anti-Nucleolin (1 
µg) for 2h. Following three further washes in PBS, cells were incubated for 1h 
with species-specific, fluorescein isothiocyanate (FITC) antibody (Jackson 
Immunoresearch, UK), at a 1:500 dilution, washed extensively in PBS and 
finally treated with Hoechst 33342 (10 µg⁄ml) for 15 minutes. Confocal 
images were taken with a Zeiss LSM 510 META confocal microscope with a 
X63 objective lens. 
 
3.23 Screening of terpenes using CETSA approach 
Several terpenes were tested to verify the ability to bind nucleolin in cell using 
CETSA approach. All molecules were characterized and purify previously 
from our group of research. More in details, Jurkat cells (1 million of cells per 
data point) were treated for 2h at 20 µM 0.1%DMSO with each molecule. The 
protocol used was the same described before; in this case cells were heated at 
55.1 ⁰C followed by western blotting analysis. 
 
3.24 Western blotting analysis 
Cell whole lysates for immunoblot analysis were prepared according to the 
standard protocol. Protein concentration was determined by DC Protein Assay 
(Bio-Rad, Berkeley, CA, USA), using bovine serum albumin (BSA) as a 
standard. Proteins were fractionated on SDS-PAGE, transferred into 
nitrocellulose membranes, and immunoblotted with appropriate primary 
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antibodies. Signals were visualized with appropriate horseradish peroxidase-
conjugated secondary antibodies and enhanced chemiluminescence 
(Amersham Biosciences-GE Healthcare, NY, USA). Densitometry of bands 
was performed with ImageJ software 
(http://rsbweb.nih.gov/ij/download.html). 
 
3.25 Statistical analysis 
Data reported in each figure are the mean values ± SD from at least three 
experiments, performed in duplicate, showing similar results. Differences 
between treatment groups were analyzed by Student’s t-test. Differences were 
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4.1 Background and aims of the projects 
Small-molecule therapeutic drugs typically exert their effects binding to one or 
a few protein targets. This critical interaction—a prerequisite of therapeutic 
drug efficacy—is often poorly understood; it can generally not be visualized in 
live cells or in entire organisms due to the lack of methods to directly measure 
drug–target engagement in a biological setting (Martinez Molina D. et al. 
2013; Adibekian A., et al. 2012). Traditional pharmacokinetics relies heavily 
on measurements of plasma concentration and is commonly described by the 
processes of Absorption, Distribution, Metabolism and Excretion (ADME). 
Unfortunately, compartmental analyses do not consider the high heterogeneity 
of drug distribution in cell. As a result, most of our knowledge is incomplete, 
as it relies on target extraction assay systems or on indirect measurements, 
where critical spatiotemporal information is lost; thus drug development and 
optimization is severely complicated. The use of invitral microscopy using 
fluorescence tool can help to overcame these problems (Vinegoni C et al. 
2015). 
Invitral microscopy approach can, indeed, offer several advantages. Recently, 
studied based on the applications of fluorescent drugs provided direct in vivo 
evidences of the presence of drug heterogeneity at tissutal (Thurber G.M. et al. 
2013), cellular (Laughney A.M. et al. 2014) and subcellular levels (Thurber 
G.M. et al. 2014) and highlighting several routes of drug failure and potential 
solutions. Additionally, cellular resolution imaging of pharmacokinetics 
enables differentiation of cell type within tissue increasing specificity of 
delivery to organs or tumors promising to decrease systemic toxicity of 
therapeutic treatment. Finally, microscopy analysis imaging can provide 
quantitative measurements with spatial and temporal information (Vinegoni C 
et al. 2015).Therefore, in order to improve and learn different techniques to 
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study the mechanism of action of small molecules, I spent a period of research 
activity at MGH (Massachusetts General Hospital) in Boston (MA, USA) 
under the supervision of Prof. Vinegoni Claudio. During this period, I 
contributed to study new methods, complementary to proteomics, allowing to 
describe the molecular mechanism of action of small molecules. In fact, the 
research group of the MGH laboratories set up the experimental conditions to 
use high-resolution intravital microscopy imaging for drug pharmacology, 
through the development of companion imaging drugs, fast imaging platforms, 
methods for automated processing, data analysis and machine learning. 
My specific aims consisted in 1) to synthesize new florescent drugs that could 
provide spatially and temporally resolved mapping, enabling live cell imaging 
of target engagement of small-molecule drugs; 2) to use chemical biology and 
bioorthogonal chemistries to develop a new method based on CETSA 
approach. Recent advances in chemical techniques have allowed the creation 
of fluorescent drugs, prodrugs and activity-based probes to interrogate target 
engagement.  
 
4.2 Fluorescence polarization applied to invitral microscopy analysis 
Firstly, I paid my attention on the use of fluorescence anisotropy based on 
fluorescence polarization (FP) coupled with invitral microscopy analysis. FP 
could be used to accurately measure drug binding in vitro and in vivo through 
multiphoton microscopy and it has many advantages. FP has been extensively 
used for different measurement in non-imaging, plate reader and kinetic in 
vitro assays to study fluorescent molecules and drug interactions (Jameson 
D.M. & Ross J.A., 2010; Weber G. 1952). The application of FP to optical 
microscopy imaging modalities could provide high resolved maps, enabling 
live cell imaging of target engagement by small-molecule drugs. However, 
this technique (Bigelow C.E et al. 2013) was used for different applications 
such as the study of membrane dynamics (Varma R. & Mayor S. 1998; 
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Sharma P. et al. 2004; Weber P. et al. 2010), the study of structures in 
biological systems (Vrabioiu A.M. & Mitchison T.J. 2006; Kampmann M. et 
al. 2011) and endogenous small molecules (Yu Q. & Heikal A.A. 2009) or 
labelled protein interactions (Gough A.H. & Taylor D.L. 1993). 
FP considers the photoselection under polarized excitation of all excited 
fluorophores aligned with the same emission dipole orientation: due to the 
presence of rotational Brownian motion, fluorophores rotate with a correlation 
time (τθ) dependent on different parameters (viscosity, molecule size and 
temperature (Lakowicz, J.R. 2006)). If the excited fluorophore is free to 
rapidly rotate on a timescale that is shorter than its fluorescence lifetime 
(τθ<<τ), emission will be isotropic (depolarized). However, when rotating 
slowly, the rotational correlation time will increase (τθ>>τ) and emission will 
be preferentially aligned along one axis (Figure 1). This happens, for example, 
when a dye is bound to a macromolecule, or to something that slows down its 
rotation. 
To characterize the extent of linearly polarized emission, fluorescence 
anisotropy (FA), a dimensionless parameter similar to FP and independent of 
excitation intensity, can be calculated. Thus, the measurements of anisotropy 
provide insight into the rotational diffusion rate of molecules, which can be 














Fig.1: Schematic representation of the two-photon photoselection. Blue bars indicate the 
distribution of emission along the two orthogonal linear polarization components as measured 
at the two detectors, for the two cases. Orange particles represent excited molecules. 
Adopted from Dubach J.M. et al. 2014 
 
I applied this methodology on the study of a new class of drugs: ADCs 
(Antibody Drug Conjugates). ADCs are formed by a highly potent cytotoxic 
drug, a linker, and an antibody and their aim is to take advantage of the 
specificity of monoclonal antibodies (mAbs) to deliver potent cytotoxic drugs 
selectively to antigen-expressing tumor cells. My aim was to study two 
different ADCs, using inivitral microsopy analysis and the ADCs fluoresce 
version, to get information about their mechanism of action in vitro and in 
vivo; indeed, their pharmacodynamics and kinetics parameters were still not 
fully described. 
The two molecules studied were trastuzumab emtansine (Figure 2A) (T-DM1, 
Kadcyla™) and milatuzumab-doxorubicin (Immu-110). The first ADC is 
composed of trastuzumab, a nonreducible thioether linker (4-[N-
maleimidomethyl]-cyclohexane-1-carbonyl [MCC]) (Lewis Phillips et al., 
2008), and the cytotoxic agent DM1 (N2′-deacetyl-N2′-(3-mercapto-1-
oxopropyl) maytansine) (Cassady J.M. et al. 2004). DM1 is derived from the 
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highly potent antitumor agent maytansine and inhibits microtubule 
polymerization (Cabanillas F et al. 1978; Chabner B.A. et al. 1978). 
The second ADC studied is a humanized monoclonal antibody targeting 
tumors that express the CD74 antigen, a cleavable linker, and doxorubicin as 
cytotoxic agent (Figure 2B). 
Fig.2: A) Chemical structure of Trastuzumab emtansine; B) Chemical structure of 
Milatuzumab-doxorubicin 
 
The first step of this study was to optimize the synthetic scheme to get the 
fluorescence versions of both drugs. Unfortunately, the expected results were 
not reached.  
Therefore, I decided to focus on the study of pharmacodynamics and kinetics 
of doxorubicin using invitral microscopy on live cells, taking advantage of its 
intrinsic fluorescence. In particular, HT1080 (Human fibrosarcoma) cells were 








Fig.3: Real time imaging of HT1080 cells following different incubation times with 
doxorubicin 10μM. Anisotropy (green/red scale) and corresponding fluorescence intensity 
(gray scale) images of doxorubicin at different representative time points during drug loading. 
Scale bar: 20µm 
 
As reported in Figure 3, real-time in vitro measurements showed that the 
amount of doxorubicin within the cells reached its maximum after 2h of 
incubation (red scale represent maximum anisotropy reached) and after 3h it 
started decreasing. The drug accumulated mainly in the nucleus of the treated 
cells, as expected since its mechanism of action. 
All these preliminary results represent a good starting point for further 
investigations and studies in vitro and in vivo. 
 
4.3 A new method based on CESTA approach  
Furthermore, during my last period there, we tried to develop a new method 
based on CESTA approach. The specific aim was to develop a new technique 
based on the combination of CETSA assay and the monitoring of specific 
fluorescence parameters (fluorescence intensity and fluorescence anisotropy) 




The CETSA approach provided by Molina and coworkers (Martinez Molina 
D. et al. 2013) is based on the detection of the soluble amount of the protein 
target thermally stabilized by its small molecule trough western blotting 
analysis. This kind of detection (immunoblot) has several disadvantages: first 
it is time-consuming compared to other techniques; second it has a high 
demand in terms of experience of the experimenter; finally it requires a deep 
optimization of the experimental conditions (i.e. protein isolation, buffers, type 
of separation, gel concentration, etc.). Therefore, with the aim to obtain a new 
technique faster, less expensive and thus useful for hightrouput screening of 
drugs, we decided to base this technique on fluorescence parameters. This 
implementation of CETSA approach could provide higher sensitivity, 
reproducibility and accuracy. 
The experimental design was optimized separately for two different classes of 
drugs: for drugs that covalently bind to their target, we focused on the use of 
the fluorescence version of the studied molecule; for drugs non-covalently 
interacting with their targets, we planned to use specific antibodies conjugated 





Fig.4: Schematic representation of new method based on CETSA approach 
 
In my period at MHG, my attention was paid on the first case, and Ibrutinib 
(Figure 5) was chose as model drug for our study; it is a well-known covalent 
inhibitor of Bruton's tyrosine kinase (Btk) and its fluorescent version of this 
drug (Ibrutinib SirCOOH) was already well characterized in vitro and in vivo 





Fig.5: Chemical structure of Ibrutinib SirCOOH 
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Therefore, HT1080 cells were treated with Ibrutinib SirCOOH at 5µM for 
2,5h of incubation time to reach the maximum equilibrium with Btk (Kim E. et 
al. 2015). Next, we heated samples in order to define the Tagg for Btk in this 
cell model. Finally, we used Btk antibody to detect the soluble amount of this 
protein in our samples. Simultaneously, the intensity of fluorescence emission 
and the fluorescence anisotropy were measured (Figure 6). 
 
Fig.6: A) CETSA was employed to monitor Ibrutinib SirCOOH cellular target engagement 
and to define the best Tagg. Therefore, treated and untreated HT1080 cells were heated and 
then was evaluated the soluble amount of NCL by western blotting; B) Apparent melting 
curves of Btk in cell. Densitometry-based quantification of western blot signals was graphed 
Bk intensities normalized to GAPDH intensities for each data point. Shown are the mean of 
three biological replicates. C) Anisotropy-based quantification of Ibrutinib SirCOOH after 
CETSA approach was graphed. 
 
 
As reported in Figure 6, the fluorescence curve and the quantitative analysis of 
the immunoblots gave the same result. In our experiments, 48.2 ºC was the 
best temperature to appreciate thermal stabilization of BTK. 
Next, EC50 of the Ibrutinib SirCOOH/Btk complex into the cell was evaluated, 
using the fluorescence intensity of Ibrutinib SirCOOH. Therefore, HT1080 
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cells were treated with a wide range of concentrations of Ibrutinib SirCOOH 
up to 5µM while incubation time and temperature were kept constant. 
Analysis of obtained results (Figure 7) gave an EC50 of 0.208µM, very close to 






Fig.7: Intensity-based quantification of Ibrutinib SirCOOH after CETSA approach to define 
EC50 was graphed. Fluorescence intensities of Ibrutinib SirCOOH was normalized to total 
intensities for each data point 
 
All these promising data represent preliminary results which will be further 
investigated and validated for following studies. 
In conclusion, thanks to this period of research at MGH, I expanded my 
knowledge and learn new techniques useful for the study of the mechanism of 
action of small molecules. Therefore, the skills I have acquired have been 
extremely rewarding in helping me to broaden my prospective about the 





Materials and methods 
 
Materials 
Fetal Bovine Serum (FBS) was from GIBCO (Life Technologies, Grand 
Island, NY, USA) and Ibrutinib SirCOOH was obtained from Ralph 
Weissleder’s laboratory. All the other reagents were from Sigma-Aldrich (St. 
Louis, MO, USA). 
 
4.4 Live cell fluorescence microscopy in cell of doxorubicin 
HT1080 (Human fibrosarcoma cell line) were seeded into a 96-well plate at 
5000 cells per well and incubated for 24h. Cells were incubated in growth 
media containing 10µM of doxorubicin 0.1% DMSO for 30min up 4h. When 
the incubation time was done, live cells were subsequently imaged on a Delta 
Vision imaging system (Applied Precision, GE Healthcare). Images were 
processed using Fiji software, an open-source version of ImageJ. 
 
4.5 CETSA approach 
 
Materials 
Antibodies: anti-Btk (anti rabbit monoclonal Y440) from Abcam (Cambridge, 
CB4 0FL, UK) 
 
4.5.1 Determination of the apparent melting curve of Btk by CETSA 
Protocol used was adopted from Jafari R. et al. 2014 but slightly modified. 
More in details, approximately 10 million HT1080 in a final volume of 10ml 
of growth media were used for each condition, in a Cell Culture Flasks (T75). 
A stock solution of Ibrutinib-SirCOOH (10μl of 5mM in DMSO) was added to 
individual flasks to get a final concentration of 5 μM of Ibrutinib-SirCOOH 
(0.1%DMSO); 10μl DMSO was used as control. Cells were gently mixed by 
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pipetting up and down at least 3 times and were incubated for 2.5h in the CO2 
incubator at 37 °C. After, cells were tripsynized and cell suspensions were 
collected and transferred to 15-ml conical tubes. Once cells were centrifuged, 
pellets of cells were washed with PBS and gently resuspended in 1ml of PBS 
supplemented with protease inhibitors to each respective tube. Each cell 
suspension was divided into 10 different tubes and the heated using PCR 
machine (Invitrogen Life Science Technologies) at different temperatures for 3 
min. 
 
The temperature used were: 
Temperature (⁰C) Sample CTR Sample Treated 
39.2 1 11 
41.2 2 12 
44.3 3 13 
48.3 4 14 
52.1 5 15 
54.6 6 16 
58.6 7 17 
61.6 8 18 
65.1 9 19 
66.9 10 20 
 
Immediately after heating, tubes were kept at room temperature for 3 min. 
After this 3-min samples were immediately snap-freezed in the liquid nitrogen 
for 3 times. Therefore, cell lysate–containing tubes were centrifuged at 
20,000g for 20 min at 4°C to pellet cell debris together with precipitated and 
aggregated proteins. Each supernatant with the soluble protein fraction was 
transferred to a new tube. Subsequently 10µl of each tubes were loaded on a 




In order to obtain fluorescence intensity and fluorescence anisotropy, 50µl of 
each supernatants were analyzed by Tecan Infinite
®
 M1000 PRO - Life 
Sciences. 
 
4.5.2 Determination of EC50 of Btk/IbrutinibSirCOOH complex by CETSA 
To perform the ITDRFCETSA experiments, equal number of HT1080 (1 million 
cells per data points) were seeded in 24 well cell culture plates in 1 ml of 
growth media ad exposed to varying concentration of Ibrutinib SirCOOH for 
2.5h of incubation time in an incubator chamber (range used from 0.005µM to 
5µM, final concentration of DMSO 0.1%). Following the incubation the drug-
containing media were removed by centrifugation cells were washed with PBS 
and prepared for CETSA experiment. In this case cells were heated at 55.1⁰C 
for 3 min and the protocol used was the same described before. All 
immunoblots were processed using Fiji software, an open source version of 
ImageJ. 
 
4.6 Western Blot analysis 
Cell whole lysates for immunoblot analysis were prepared according to the 
standard protocol. Protein concentration was determined by DC Protein Assay 
(Bio-Rad, Berkeley, CA, USA), using bovine serum albumin (BSA) as a 
standard. Proteins were fractionated on SDS-PAGE, transferred into 
nitrocellulose membranes, and immunoblotted with appropriate primary 
antibodies. Signals were visualized with appropriate horseradish peroxidase-
conjugated secondary antibodies and enhanced chemiluminescence 
(Amersham Biosciences-GE Healthcare, NY, USA). Densitometry of bands 





4.7 Statistical analysis 
Data reported in each figure are the mean values ± SD from at least three 
experiments, performed in duplicate, showing similar results. Differences 
between treatment groups were analyzed by Student’s t-test. Differences were 
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